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Abstract 
 Equine Gastric Ulcer Syndrome (EGUS) is a common condition of the horse, 
affecting a broad range of horse usages and types.  Recently the terminology of the 
syndrome has been expanded to include terms Equine Squamous Gastric Disease 
(ESGD) and Equine Glandular Gastric Disease (EGGD) to describe diseases of the 
squamous and glandular mucosa of the stomach, respectively.   
 Omeprazole, a proton pump inhibitor that blocks acid production, is considered the 
treatment of choice for EGUS and it has been widely used for this purpose for nearly 20 
years.  Yet, surprisingly, despite its widespread use little is known about the factors that 
affect its efficacy, such as the impact of formulation, diet and dose.  Further, although it is 
commonly believed that the once daily administration of omeprazole results in durations of 
acid suppression exceeding 24 hours, there is conflict in the literature as to the validity of 
this belief.  Recent clinical studies have demonstrated that the healing rate for EGGD is 
inferior to that of ESGD, raising further questions as to the efficacy of omeprazole under 
clinically relevant conditions.  One potential reason for this observation is that the duration 
of intra-day acid suppression required for healing of ESGD may be less than that for 
EGGD.  This, coupled with the possibility that once daily administration of omeprazole may 
not result in acid suppression for the entire 24 hour treatment interval, provides a potential 
explanation for the poor EGGD healing rates that have been recently reported. 
 The purpose of this thesis was to investigate the factors that affect the efficacy of 
omeprazole in the horse.  The studies were conducted in four parts; firstly, the effect of 
formulation and diet on the pharmacokinetics of omeprazole were investigated; secondly, 
a model that allows continuous intra-gastric pH measurement under clinically relevant 
conditions was developed; thirdly, the impact of diet and dose on the pharmacokinetics 
and pharmacodynamics of omeprazole were investigated; and lastly, the relationships 
between key pharmacokinetic and pharmacodynamic variables were investigated. 
 The findings of the study suggested that some method of physical protection is 
required to protect the omeprazole from degradation in the acidic environment of the 
stomach and to improve bioavailability.  However, significant differences were not present 
between formulations utilising the two most common forms of protection, namely the use 
of enteric coated granules in paste or buffering of the formulation.  This suggests that the 
method of protection, buffering of the formulation or the use enteric coated granules in 
paste, used is less important than protection per se.  The earlier studies of the thesis 
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suggested that an effect of feeding may be present on the pharmacokinetics of 
omeprazole but a statistically significant effect could not be demonstrated.  Similarly, the 
latter studies suggested that diet may play a role in bioavailability with ad libitum roughage 
diets impairing absorption, but no statistically significant effect was present.  A wide 
degree of inter-individual variation was present and the small numbers of animals used 
may have meant that the power of the studies was inadequate to document such an effect.  
However, an effect of diet on the pharmacodynamics of omeprazole was present with a 
lower magnitude and duration of acid suppression consistently observed in ad libitum 
roughage diets when compared with high grain/low fibre diets.  An inconsistent effect of 
dose on the pharmacodynamics of omeprazole was observed with the effect the most 
pronounced in the high grain/low fibre diet.  In contrast, no effect of dose was present in 
the ad libitum roughage diet, although the overall efficacy of both doses was poor under 
these conditions.  Lastly, the key pharmacokinetic and pharmacodynamic parameters 
correlated poorly, which suggested that plasma concentrations are poorly predictive of 
pharmacodynamic response in the horse, although the reasons for this are unclear as in 
other species area under the curve is predictive of pharmacodynamic response. 
 The results of the present studies suggested that both diet and dose impact on the 
pharmacodynamics of omeprazole in the horse.  The overall low efficacy of omeprazole 
under the ad libitum roughage dietary conditions was surprising but potentially significant.  
Firstly, it provides a potential explanation for the poor healing rates recently reported for 
EGGD.  Secondly, it suggests that singular dosing recommendations that encompass all 
horse types and usages, as currently used, may not be appropriate.  Instead the use of 
dosing recommendations that take into account the diet and management of the horse 
may be advantageous.  Lastly, the findings of the thesis demonstrate that further studies 
into alternative dosing regimens, such as higher dose or twice daily administration, or the 
investigation of alternative therapeutic agents are required to address the need a 
therapeutic approach that allows for effective acid suppressive therapy in horses on high 
roughage diets. 
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Chapter 1  
1.1 Introduction 
The horse’s stomach is a single chamber with two different linings. The top half of 
the stomach is lined by a squamous mucosa which is akin to the lining of the oesophagus 
while the bottom half of the stomach is lined by a glandular mucosa akin to the lining of the 
human stomach.  The term Equine Gastric Ulcer Syndrome (EGUS) was first adopted in 
1999 to describe ulcerative diseases of the stomach and its use has become widespread. 
However, the term is commonly misrepresented and recently an attempt has been made 
to clarify its meaning with an emphasis on recognition that the term EGUS refers to a 
syndrome, within which numerous disease entities exist [1].  To expand the terminology 
the terms Equine Squamous Gastric Disease (ESGD) and Equine Glandular Gastric 
Disease (EGGD) have been proposed by the European College of Equine Internal 
Medicine (ECEIM) Consensus Panel to describe diseases of the squamous mucosa and 
glandular mucosa, respectively [1]. 
Regardless of the lesion type omeprazole is recommended as the treatment of 
choice [1], consistent with the mantra in human medicine of “no acid, no ulcer’ [2].  Early 
studies investigating the pharmacodynamics of omeprazole in the horse suggested that it 
has a 24 hour duration of activity following enteral administration [3,4] and its efficacy in 
the treatment of ESGD in a number of clinical studies [5–7] appeared to support this 
conclusion. However, recent studies performed by one of the authors in the lead up to this 
thesis demonstrated that only 25% of EGGD lesions heal with 28-35 days of omeprazole 
therapy at 4.0 mg/kg per os (PO) once daily in direct contrast to an ESGD lesion healing 
rate of 78% in the same studies [8–10].   
The reasons for the lower EGGD response rate are not immediately apparent.  One 
possibility is that the duration of intra-day acid suppression required for healing of ESGD 
may less than that required for healing of EGGD. A 2003 study by Merritt et al suggested 
that, in contrast to earlier reports, the duration of acid suppression with 4 mg/kg PO once 
day may be ≤ 14 hours [11].   As such, it may be that ≤ 14 hours of acid suppression is 
adequate for ESGD healing, while EGGD healing may require acid suppression of a longer 
duration.  An alternative explanation is that the duration of therapy with current treatment 
guidelines is inadequate for glandular healing to occur.  In humans, the duration of therapy 
for glandular ulceration is dependent on primary cause of the lesion [2].  For Helicobacter 
pylori associated ulcers, triple therapy combining antimicrobials and acid suppression 
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consistently yields first line eradication rates of greater than 80% with 7 – 14 days of 
therapy [2].  In contrast, Non-Steroidal Anti-Inflammatory Drug (NSAID) induced glandular 
ulceration requires longer treatment duration with 84% and 100% of patients healing at 8 
and 12 weeks, respectively, in response to acid suppression therapy and discontinuation 
of NSAID therapy in one study [12]. A third potential explanation is that adjunctive therapy, 
such as antimicrobials, may be required.  However, to date, a definitive role for bacteria in 
the pathogenesis of ESGD or EGGD has not been demonstrated and the current ECEIM 
consensus statement position is that, in line with the professions responsibilities regarding 
the responsible use of antimicrobials,  the routine use of antimicrobials is not justified due 
to a lack of evidence to support either a role for bacteria in the pathogenesis of EGGD, or 
the efficacy of antimicrobials in the treatment of EGGD [1].  
Given that acid suppression is considered a cornerstone of therapy in human 
medicine, regardless of the inciting cause or use of adjunctive therapy [2], and the conflict 
that exists in the literature as to duration and magnitude of acid suppression achieved with 
omeprazole in the horse at current dosing regimens; the authors considered that further 
investigation into the efficacy of omeprazole in the horse was warranted before longer 
treatment durations, or the use of adjunctive therapies such as antimicrobials, were 
investigated in detail.  Further, it was considered that investigation into factors that may 
affect efficacy such as formulation, diet and dose was warranted. 
1.2 Literature review 
1.2.1 Diagnosis 
Gastroscopy is currently considered the only reliable ant-mortem method for 
definitively diagnosing EGUS.  There are currently no reliable haematological or 
biomechanical markers available to aid in diagnosis of gastric ulceration. A sucrose 
permeability test has shown promise for non-invasive detection of gastric ulcers [13,14], 
but to date, the diagnostic accuracy of the test has not been reported in clinical cases. An 
initial report suggested that faecal occult blood may be a useful screening test [15] but a 
more recent study found no association between the presence of gastric ulcers and the 
detection of either faecal albumin or haemoglobin [16]. 
Once identified on gastroscopy, assessment of the severity of lesions is most 
commonly achieved by assigning a grade that describes the mucosal appearance at 
different anatomic sites. In 1999 the Equine Gastric Ulcer Council proposed a 0-4 grading 
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system designed to assign severity based upon lesion depth, size and number [17] and 
recommended that the system should be adopted for both clinical and research use. 
Although a number of other grading systems have been described [5,18,19], a further 
study recommended that the 0-4 Equine Gastric Ulcer Council system be adopted as the 
standard EGUS scoring system due to its ease of use, and the repeatability and 
correlation of grades between examiners [20] and this recommendation has been further 
supported by the recent ECEIM consensus statement [1].  
In contrast to ESGD there is minimal data on the validity of grading EGGD lesions. 
It appears that subjective visual assessment of severity and the histopathological 
appearance of the epithelium and mucosa correlate poorly [21] and the clinical relevance 
of the different manifestations of glandular disease are yet to be well evaluated. Lesions 
can differ in their epithelial appearance (hyperaemic, haemorrhagic, fibrinosuppurative, 
ulcerated) and in their mucosal contour (depressed, flat, raised) and variation in the 
histologic appearance of glandular lesions is reported [21]. Considering this; at present it is 
not recommended that a hierarchical grading system such as that used for ESGD be used 
for EGGD [1].  Instead, it is recommended that EGGD lesions be graded based on their 
anatomical location and gross appearance [1]. 
It is intuitive to believe that more severe lesions are more likely to result in clinically 
important disease and the use of hierarchical systems implies more severe disease with 
higher grades. However, although it has been suggested that there is a correlation 
between the severity of gastric ulceration and the severity of clinical signs [22,23], there is 
little evidence to support this notion [1].  Accordingly, prevalences are traditionally reported 
using a dichotomous assessment of normal or abnormal.  Treatment outcomes are 
traditionally reported in a similar manner as healed or not, although improvement by at 
least 1 grade has also been used as measure of partial healing in some studies [5,6,8–
10,24]. 
1.2.2 Prevalence 
The prevalence of ESGD mirrors exercise intensity with the risk of disease 
increasing as the intensity of work increases.  The highest prevalence has been reported 
in Thoroughbred racehorses, with > 70% of animals affected across a wide range of 
studies [19,25–27], and in competing endurance horses with 93% of animals affected [28]. 
Standardbred racehorses are also commonly affected (63 – 87% of animals [29,30]). 
However, ESGD is not solely a disease of high performance horses and it is seen across a 
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wide range of other horse types with 69% of horses used for a variety of purposes affected 
in a Danish study [31].  The ESGD prevalence has also been reported as 40-58% in show 
horses [32,33] and  54% in polo horses [34]. The prevalence of ESGD in horses at rest is 
variable, but it is typically lower and, when observed, tends to be less severe.   An ESGD 
prevalence of 22% was recently reported in a population of feral horses [35]. 
The prevalence of EGGD has been less well documented until recently. Australian 
Thoroughbred racehorses have prevalences of between 47% [27] and 65% [8]. In 
endurance horses the prevalence is 16% outside of the competition period and 27-33% 
during the competition period [28,36]. A study in the UK found EGGD in 54% of 191 leisure 
horses and in 64% of 493 sport horses presenting for gastroscopic evaluation [37]. 
Comparably, 72% of Warmblood showjumpers [33], 69% of polo horses [34] and 57% of 
horses used for a variety of purposes have been reported to have EGGD in population 
studies [31,38].  An EGGD prevalence of 30% has been reported in a population of feral 
horses [35].The majority of EGGD lesions in all of the above studies were found within the 
pyloric antrum.   
1.2.3 Pathophysiology 
Horses are constant but variable secretors of gastric acid [39] and the median pH of 
the ventral stomach of 3.0 over a normal 24-hour period reflects this [40]. Under normal 
conditions the consumption of roughage creates a basketball sized bolus of feed in the 
stomach that acts as a buffer to absorb gastric acidity. Further, swallowed saliva is likely to 
result in significant buffering at the level of the cardia.  As a result the gastric pH at the 
level of cardia has a median value of approximately 7.0 [40].  Squamous ulceration occurs, 
fundamentally, as a result of increased exposure of the squamous epithelium, which has 
limited defence mechanisms, to highly acidic gastric contents [41,42].  Endogenous 
production of hydrochloric acid is likely the dominate aggressive agent, as discussed 
below, although duodenal bile salts may also play a role [43].  Any disruption of the normal 
stratification of gastric pH results in an increased risk of ESGD and damage occurs rapidly 
with evidence of acid injury evident within 30 minutes of exposure in vitro [44].  Exercise, 
which results in changes in intra-abdominal pressure and the pushing of acidic contents 
into the proximal stomach [45], is considered a key contributory factor in clinical disease. 
The fermentation of non-structural carbohydrates consumed in the diet into short-
chain fatty acids are likely also to contribute to squamous mucosal injury [46]. A consistent 
effect is observed with increased starch/grain intake associated with an increased risk of ESGD in 
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animals working at various levels of intensity in a number of studies. A marked increase in 
ulceration when non–exercising animals were stabled and fed grain at 1% of BW, 1 hour before 
hay was fed has been demonstrated [47]. Similarly, exceeding 2 g/kg BW of starch intake per day 
has been associated with an approximately two-fold increase in the likelihood of ESGD grade ≥ 2/5 
[48]. However, the high rate of ESGD healing observed with omeprazole treatment, and in 
the absence of risk factor reduction [5–9,49,50], provides indirect evidence that gastric 
acid is the dominant erosive agent and that the role of short-chain fatty acids is likely to be 
less important.  
The glandular mucosa differs fundamentally from the squamous mucosa in that 
under normal physiological conditions it is exposed to highly acidic gastric contents with 
the pH in the ventral portion of the stomach relatively stable at around 3 [40].  In contrast 
to ESGD, which occurs as a result of increased acid exposure in a region with limited 
defence mechanisms, EGGD is believed to result from a breakdown of the normal defence 
mechanisms that protect the mucosa from acidic gastric contents, although the specific 
mechanisms by which this occurs have yet to be elucidated.   
Non-Helicobacter pylori, non-NSAID ulceration, otherwise known as idiopathic 
peptic ulcer disease, does occur in humans but until recently has been considered rare [2].  
However, recent publications have suggested that between 10% and 30% of peptic ulcers 
in certain human populations may be idiopathic in nature [51].  Interestingly, largely 
mirroring our current state of knowledge in the horse, the aetiology of idiopathic ulceration 
in humans is unknown and treatment is empirically with proton pump inhibitors [51].  
Further, the efficacy of acid suppression in the prevention of reoccurrence is questionable 
[52] further mimicking the current situation in the horse. 
The role of bacteria in EGGD is controversial and a recent study suggested that 
both gastric-adapted bacteria and opportunistic pathogens may play a role in squamous 
ulceration [53].  Whether the situation is similar in the glandular mucosa is unknown but  
Helicobacter-like organisms have been identified in horses affected with EGGD in some 
studies [54,55].  However, other studies have failed to identify such organisms [21,38] and 
it appears, based on current knowledge, that it is unlikely that H. pylori is the primary 
causative agent of EGGD [1]. The role of secondary bacterial infection in the worsening or 
perpetuation of EGGD is unclear at this point in time. 
Equally controversial is the role of NSAIDs in the development of EGGD.  A variety 
of NSAIDs, namely flunixin, phenylbutazone and ketoprofen, have been shown to have 
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ulcerogenic potential at doses only 50% higher than typically recommended [56].  
However, at clinical doses phenylbutazone and suxibuzone did not induce gastric 
ulceration when administered for 15 days [57] and the administration of NSAIDs was not 
identified as a risk factor for ESGD or EGGD in a recent study [58], nor was it identified as 
a risk factor for ESGD in two earlier studies [19,26].  
1.2.4 Risk factors 
 A large number of management changes are imposed upon horses with the 
commencement of training, many of which have been documented to increase the risk of 
ESGD.  These include exercise [45], high concentrate/low roughage diets [59], fasting [60], 
transport [61], stall confinement [60], the administration of hypertonic electrolytes [62] and 
intermittent access to water [48].  Further, significant associations have been shown between 
ESGD and individual trainers, a metropolitan yard location (horses trained in urban areas were 3.9 
x more likely to have gastric ulcers), a lack of direct contact with other horses, solid barriers instead 
of rails, and talk rather than music radio in the barn [63]. Induction of ESGD can be rapid, 
occurring within 7 days in some studies [61,64] and the risk of disease increases with time 
in work [58].   
To date, the risk factors for EGGD have been poorly described.  In a study on 
Thoroughbred racehorses risk factors identified for EGGD were gender (colts are at 
reduced risk), trainer, no grass turnout, horses in direct contact with each other, horses not 
fed haylage, horses fed unprocessed grain, horses that were infrequently fed a complete 
diet, horses that underwent fast exercise on fewer days of the week and horses that went 
swimming [58]. In contrast to the wide range of factors identified in Thoroughbred 
racehorses, no effect of age, gender, use or month of presentation was found on ulcer 
location or type in a large study of UK leisure and sport horses [37].  Two recent studies in 
Warmblood showjumpers and polo horses found that horses competing at lower levels 
more likely to have glandular ulcerations than those competing at elite level [33,34], 
suggesting that glandular ulceration may negatively impact performance. Straw feeding and 
a lack of access to water in the paddock have been associated with an increased risk of EGUS in 
general [48]. 
1.2.5 Treatment 
The mantra “no acid, no ulcer’ acid suppression is considered a cornerstone of 
gastric ulcer management in humans [2].  Consistent with this, the recent ECEIM 
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consensus statement advised that acid suppression should be a cornerstone of treatment 
of ESGD, for which its use is well established, and EGGD, despite the failure to identify a 
cause (or causes) at this point in time [1].   Acid suppression does not directly contribute to 
healing.  Instead the removal of on-going insult results in an environment conducive for 
healing to occur.  A variety of drugs including proton pump inhibitors (PPIs), H2-receptor 
antagonists and antacids have been used for this purpose.     
Omeprazole is the only PPI that has been studied under clinical conditions in the 
horse and until recently the majority of studies have reported treatment response rates for 
ESGD.  It is traditionally believed that omeprazole irreversibly binds to, and inhibits, the 
H+/K+ ATPase (proton) pump that secretes HCl with new pumps needing to be made 
before acid production resumes [65].  However, the irreversible nature of the binding has 
been questioned as the rate of recovery of acid production exceeds that expected with de 
novo biosynthesis of new pumps [66].  Instead it is believed that a reduction in the 
disulphide bond between omeprazole and the proton pump may result in reversal of the 
inhibition [66].  Supporting this hypothesis, a study in rats documented that the half-time of 
ATPase restoration was only 15 hours, in contrast to 54 hours as predicted by de novo 
biosynthesis [67]. 
Other treatment modalities have been described in the horse but two studies have 
demonstrated omeprazole’s superior efficacy.  In a study comparing the likelihood of 
ESGD being present only commercial omeprazole decreased the ESGD risk below that of 
a placebo, in contrast to buffers, sucralfate, H2-receptor antagonists and compounded 
omeprazole, none of which had any demonstrable benefit [68]. Similarly, omeprazole was 
demonstrated to be superior to ranitidine in a clinical study in Thoroughbred racehorses in 
Australia [50].     
GastroGard® (Merial, Duluth, GA, USA), which utilises a buffer to protect the 
omeprazole [11],  is the best studied formulation of omeprazole for the treatment of ESGD 
at its registered dose of 4 mg/kg PO once daily for 28 days as recommended by the 1999 
EGUS Council [17] with ESGD healing rates of approximately 70 – 80% consistently 
reported [5–7,49,50].  Recently, the use of lower doses of an enteric coated formulation 
(Gastrozol®, Virbac, Milperra, NSW, Australia) has been evaluated and, under certain 
conditions,  doses as low as 1 mg/kg PO once daily have been shown to be as efficacious 
as 4 mg/kg PO once daily in the treatment of ESGD [8].  Similarly, Gastrozol® at 1 mg/kg 
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PO once daily was equally effective as GastroGard®  at 4 mg/kg PO once daily in a recent 
clinical trial [69].   
Ranitidine and cimetidine work via competitively blocking the H2-receptor on the 
parietal cell and their efficacy is dependent on maintaining plasma concentrations.  
Ranitidine, most commonly used at 6.6 mg/kg PO q 8 hours, has been shown to effectively 
suppress gastric acidity in experimental studies [39,70–72] and, although inferior at a 
population level [50,68], it provides an option for acid suppressor therapy where 
omeprazole is not available or ineffective [1].  Antacids can effectively reduce gastric 
acidity but their effect is short lived (≤ 2hours) [70,73] and there are no clinical studies to 
support their use. 
Until recently treatment recommendations for EGUS have not differentiated 
between ESGD and EGGD disease.  However, in a series of recent studies only 25% of 
EGGD lesions healed with 28-35 days of omeprazole therapy at 4.0 mg/kg PO once daily 
in direct contrast to an ESGD lesion healing rate of 78% in the same studies [8–10]. The 
reasons for the poor response of EGGD to omeprazole therapy are not understood but 
three factors warrant consideration namely; the duration of intra-day acid suppression 
achieved with current dosing regimens, the duration of therapy required and the use of, or 
potential need for, adjunctive or alternative therapies.  As discussed in the introduction; the 
authors believe that investigation into the duration of action, and the factors that affect it, is 
warranted before further investigation of adjunctive therapies or longer durations of 
treatment. 
1.3 Pharmacokinetics of Omeprazole in the Horse 
The pharmacokinetics of intravenous omeprazole have been described [74], as has 
intramuscular administration [75].   The pharmacokinetics following intravenous 
administration have been described as fitting a two-compartment model with a short β-half-
life (t1/2) of 30 minutes [75] (compared with approximately 1 hour in humans and dogs 
[76]).  Intramuscular administration has a bioavailability (F%) of 70-80% and a t1/2 of 45-60 
minutes [75].  Despite its widespread use, surprisingly little is published on the 
pharmacokinetics of oral omeprazole and the factors that potentially influence the 
pharmacokinetics such as formulation, dose and diet are poorly investigated.   
Of these formulation has been partly investigated. It has been previously reported 
that omeprazole is acid labile and that it requires some form of protection because 
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exposure to acid in the stomach followed by alkalinisation in the small intestine renders the 
drug inactive before absorption can occur [11].  This is primarily achieved by one of two 
mechanisms, either through the use of enteric coating, either as enteric granules that are 
encapsulated or suspended in a paste, or by combining buffering agents with the 
omeprazole in a paste formulation.  Plain omeprazole is available as a compounded 
medication in the USA and Australia with apparently little or no buffering present [11,77].   
Early studies reported the pharmacokinetics of enterally administered omeprazole 
but were likely limited, at least in part due the relatively poor sensitivity of the analytical 
methods used.  One study evaluating the administration of enteric coated pellets in 
gelatine capsules at 0.7 mg/kg PO once daily found that, despite suppression of acid 
production being documented in all horses, the Area-Under-the-Curve (AUC) could only be 
determined for 5 out of 8 horses due to low concentrations of the drug being detected [78].  
For those 5 horses a bioavailability of 12% and 14% on days 1 and 5 respectively, was 
reported [78]. In contrast to the effect observed in humans where bioavailability of enteric 
coated capsules increases by about 60% over 8 days of treatment [79], no cumulative 
effect of dosing was observed on either AUC or bioavailability [78].  A second, similar 
study evaluating 1.4 mg/kg of enteric coated pellets in gelatine capsules reported similar 
results with bioavailability only calculable for 5 of the 8 horses studied. In those horse the 
bioavailability was reported as 6% on day 1 and 13% on day 5 [4] suggesting that a 
cumulative effect of multiple dosing may be present.  However, no consistent effect on 
AUC was observed and caution should be drawn in drawing any conclusions on an 
incomplete data set. 
The pharmacokinetics of GastroGard®, the predominant formulation used in the 
horse globally, have been poorly described.  A single study [3] reported its 
pharmacokinetics with a time to maximal serum/plasma concentration (Tmax) following oral 
administration of approximately 1.5 hours.    Until recently GastroGard® was protected by a 
global patent that was recognised in the majority of developed countries with the notable 
exception of Australia and New Zealand.  This may in part explain why no direct 
comparisons of the difference formulations were published in the peer reviewed literature 
until recently.  Similarly, the high efficacy of GastroGard® in the treatment of ESGD likely 
reduced interest in investigation into factors that affect its efficacy.  Recent reports of its 
relative inefficacy in the treatment of EGGD [8–10] and the recent expiration of the global 
patent have resulted in an increased level of interest in factors that affect it’s, and 
omeprazole in general’s, efficacy.  To this effect a recent publication reported the 
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comparative pharmacokinetics of GastroGard® and Gastrozol® [69].  The 
pharmacokinetics of GastroGard® at 4 mg/kg PO once daily were compared with those of 
Gastrozol® at 1 mg/kg PO once daily alongside the outcome of clinical EGUS cases.  No 
difference in endoscopic outcome was reported although it warrants note than in general 
only mild lesions were present.  The bioavailability, reported as AUC, for Gastrozol® was 
1.26 times higher than for GastroGard® although not statistically significant effect was 
present due to the wide 95% confidence interval (0.56-2.81) [69].  However, interpretation 
of the results is difficult as the dose of omeprazole used for GastroGard® of 4 mg/kg PO 
once daily differed from the dose of 1 mg/kg PO once daily used for Gastrozol®.  Yet, to 
the authors’ knowledge, direct comparisons of dose and as such dose linear 
pharmacokinetics have not been demonstrated for omeprazole in the horse.  As such it 
cannot be assumed that the pharmacokinetics of the two doses are equivalent, and the 
direct comparison of different doses is not appropriate.   
Likewise the potential impact of feeding on reducing bioavailability has been 
sparsely reported.  A single study reported the effect of feeding on a GastroGard®  wherein 
the mean (± standard error) AUC for omeprazole (as reported in ng h/mL) for fed horses 
was 633 (± 120) and 678 (± 150) on days 1 and 14, respectively, in fasted horses 
compared with 1808 (± 198) in fasted horses on day 5 [3].  This suggested that feeding 
may reduce the average bioavailability to as little as 1/3 of fasted values.  Brief mention of 
the finding was made in the study’s discussion yet little emphasis has been placed in diet 
subsequently and the dosing recommendations for commercial formulations do not 
distinguish between administrations to fed or fasted animals.  This is surprising given that 
the diet of different horse usage types varies greatly, from the roughage based diet of 
pleasure horses to the high grain/low fibre diet of high performance horses such as 
racehorses [80]. Similarly, feeding has been shown to reduce absorption of omeprazole in 
humans and human patients are advised to take omeprazole prior to eating [81,82].  
1.4 Pharmacodynamics of Omeprazole in the Horse 
The earliest reported studies on oral omeprazole in the horse reported the use of 
enteric-coated pellets in gelatine capsules administered via naso-gastric tube.  In one 
study 0.7 mg/kg of enteric coated pellets was administered once daily via nasogastric tube 
for 5 days [78].  Samples of gastric fluid were collected via an indwelling gastric cannula to 
measure gastric acidity and acid output on days 1 and 5.   Samples were collected in the 
period of 5-6 hours post administration and the horses were then infused with pentagastrin 
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for hours 6-8 to induce gastric acid output.  Samples were collected for a second time 
period at 7-8 hours post administration (1 hour after the commencement of the 
pentagastrin infusion).  Minimal effect of treatment was observed on day 1 but by day 5 all 
four parameters of acid production assessed (basal and pentagastrin stimulated acid 
output and acidity) were reduced by approximately 70%.  Basal gastric fluid pH was 
unchanged in the treated horses but pentagastrin stimulated values rose from 1.7 ± 0.7 on 
the control day to 4.6 ± 2.1 on day 5 [78].  The improved efficacy on day 5 is consistent 
with reports from humans where day 5 levels of acid suppression following daily 
administration are greater than those observed on day 1 [83].  
A second study reported the administration of 1.4 mg/kg of enteric coated pellets in 
gelatine capsules for 6 days [4].  Similar to the study described above, gastric acid output 
and acidity were determined at basal levels between 5-6 hours post administration 
followed by a 2 hour pentagastrin infusion and repeated measurements 7-8 hours post 
administration on days 1 and 5.  On day 7, a third gastric secretion test with pentagastrin 
stimulation was performed between hours 24–27 after administration of the 6th dose.     
Similar results to the above study were reported for days 1 and 5 with the levels of 
suppression achieved on day 5 approximately 80% of control values in pentagastrin 
stimulated horses while basal acidity and acid output was decreased by 70% at 5-6 hours 
on day 5 in treated horses. Basal pH increased to 6.2 ± 2.0 on day 5 at 5-6 hours 
compared with 3.2 ± 2.0 on the control day and pentagastrin stimulated pH at 7-8 hours on 
day 5 was 4.6 ± 2.2 compared with control values of 1.7 ± 0.7 [4].  Together these findings 
suggested that a dose response was present with the higher dose used in this study (1.4 
mg/kg PO once daily) more efficacious than the dose reported in the earlier study (0.7 
mg/kg PO once daily) [78].  On day 7 basal acid output at 24-25 hours was decreased by 
90% while acidity was decreased by 66%.  Mean basal pH (5.6 ± 1.7) appeared higher 
than control values (3.2 ± 2.0) but was not statistically significantly different.  Pentagastrin 
stimulated acid output at 26-27 hours was reduced by 72% and mean pH (3.2 ± 1.5) was 
significantly higher than control values (1.7 ± 0.7) [4].  These findings suggested that at 
this dose the duration of activity of omeprazole may be at least 27 hours in the horse 
under the conditions studied.   
Omeprazole pharmacodynamics were further reported in a study where omeprazole 
was administered via nasogastric tube as acid stable granules in a methylcellulose paste 
at 1.5 and 5.0 mg/kg once daily, or as an oral paste of acid stable granules at 1.5 mg/kg, 
or an oral paste of omeprazole powder at 3.0 mg/kg PO once daily [84].  Basal gastric acid 
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output and pH were determined 2-3 hours post administration followed by a 3 hour 
pentagastrin infusion (hours 3-5) during which stimulated values were recorded.  A gastric 
cannula model was used and horses were fasted 18-24 hours prior to each study. A clear 
dose effect was present between the two doses of acid stable granules studied with 5.0 
mg/kg PO once daily resulting in 97% and 98% suppression of basal and pentagastrin 
stimulated output respectively on day 5.  In comparison basal and pentagastrin stimulated 
output were reduced by only 53% and 57% respectively in the 1.5 mg/kg PO once daily 
group [84].  Similarly, mean gastric pH was 7.2 (basal) and 6.8 (pentagastrin stimulated) in 
the 5.0 mg/kg groups, compared with 2.6 (basal) and 2.2 (pentagastrin stimulated) in the 
1.5 mg/kg group.  No differences were present between days 5, 12 and 19 of treatment.   
Administration of plain omeprazole powder as a paste at 1.5 mg/kg produced 
similar results to those reported for the nasogastrically administered acid stable granules 
above [84].  A dose effect was present as when the daily dose of plain omeprazole powder 
was increased to 3.0 mg/kg it resulted in a reduction of gastric acid output by 82% (basal) 
and 77% (pentagastrin stimulated) from baseline.  Likewise, in the 3.0 mg/kg group mean 
pH was 5.2 (basal) and 4.7 (pentagastrin stimulated) compared with 3.4 (basal) and 3.0 
(pentagastrin stimulated) in the 1.5 mg/kg group [84].  The authors concluded that the 
results achieved with the use of acid stable granules in paste form were comparable to 
those achieved using nasogastric intubation as the means of administration and that the 
use of paste formulations of omeprazole for inducing acid suppression was clinically 
feasible. 
The same year another study reported the efficacy of an omeprazole paste at 4 
mg/kg and 5 mg/kg PO once daily [3].   Basal and pentagastrin stimulated gastric acid 
output and pH was evaluated 5-8 hours after 5 doses, 13-16 hours after 10 doses and 21-
24 hours after 15 doses.  Similar to the above studies horses were fasted for 18 – 24 
hours prior to the initiation of each collection.  The results of the study suggest that at 4 
mg/kg PO once daily profound acid suppression was achieved with both basal and 
pentagastrin stimulated gastric acid output reduced by 99% on day 5 (hours 5-8) and by 
83% (basal) and 90% (pentagastrin stimulated) on day 15 (hours 21-24) [3].  Similarly 
gastric pH was 7.4 ± 0.07 and 7.03 ± 0.22 (basal and pentagastrin stimulated, 
respectively) at 6-8 hours on day 5, 6.51 ± 0.27 and 5.87 ± 0.44 (basal and pentagastrin 
stimulated, respectively) at 14-16 hours on day 10 and 5.5 ± 0.47 and 4.32 ± 0.62 (basal 
and pentagastrin stimulated, respectively) at 22-24 on day 15. No differences were present 
between the 4.0 mg/kg and 5.0 mg/kg dose [3]. The findings of this study were considered 
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good evidence of omeprazole’s twenty-four hour duration of activity following oral 
administration in the horse. 
This statement is challenged by a more recent study performed by Merritt et al 
using pH probes inserted retrograde into the indwelling gastric cannula [11].  In this study 
GastroGard® was compared to three compounded formulations of omeprazole with intra-
gastric pH of the ventral stomach continuously recorded for 24 hour periods in fed horses.  
In this study the percentage of time above a pH of 4 was used as the determinant of 
efficacy as this is widely accepted in human medicine as the primary determinant of 
symptomatic control and healing for the treatment of gastroesophageal reflux disease 
(GERD), a condition the has many similarities with ESGD [11].  The findings of the study 
were striking in that the mean hourly % time above pH 4 for GastroGard
®
 was only 14 and 
11 hours on days 2 and 7 of treatment, respectively.     
If the effect described by Merritt et al [11] is repeatable then it provides a potentially 
simple explanation for the discrepancy in the healing rates of ESGD and EGGD as 
discussed in the preceding section.  Simply, current dosing regimens of omeprazole may 
not result in an adequate duration of acid suppression, particularly in the ventral stomach, 
to allow EGGD lesions to heal. 
1.5 Models of Intra-Gastric pH Measurement in the Horse 
A variety of models have been used to measure intra-gastric pH in the horse and 
given the significance placed on the studies’ findings, the authors believe that discussion 
of the different models is warranted.  A review on the history of intra-gastric measurement 
in the horse has recently been published [85] with the earliest report dating back to 1933 
([86] cited in [85]) when a gastric fistula was created in a horse allowing collection of 
gastric fluid and quantification of daily output from the live animal .    
Early work in the 1990s evaluating the efficacy of different formulations of 
omeprazole in the horse was primarily performed using a gastric cannulation model 
[3,4,75,78,84] which was considered the model of choice at the time [85].  An advantage of 
this method was that it allows the measurement of gastric fluid pH, electrolytes and 
prostaglandins and the calculation of total daily gastric acid output.  However, a key 
disadvantage was that it may not be truly reflective of clinical conditions since the horses 
in the studies cited above were fasted for 18 – 24 hours prior to the collection of gastric 
fluid.  Three factors associated with fasting potentially influence the interpretation of the 
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studies’ results.  Firstly, it is not apparent from the publications if the horse were fasted at 
the time of administration of the omeprazole. This is a potentially relevant as the 
bioavailability of omeprazole may be affected with serum levels of omeprazole, as 
measured by AUC, reported from fed horses being as little as 1/3 of levels obtained from 
fasted horses [3] depending on the formulation studied. Additionally, it is well recognised 
that omeprazole is most effective on parietal cells that are being stimulated [87] and the 
act of fasting either prior to, or following, omeprazole administration, potentially influences 
the interpretation of the efficacy of omeprazole.  In the above studies, pentagastrin 
stimulation was used in an attempt to address this, but it is not known if the pentagastrin 
stimulation model used reliably replicates the effect of feeding induced parietal cell 
stimulation. Lastly, it has been suggested that fluid collected from fasted horses is likely to 
be influenced by contributions from both saliva and duodenal reflux [11], both of which are 
highly alkaline, which may confound interpretation of fluid retrieved.      
A modification of the gastric cannulation model wherein a pH probe is fitted 
retrograde into the gastric cannula has been described [11].  This model allows the 
measurement of intra-gastric pH regardless of dietary management and as such it 
obviates some of the concerns raised with the fluid collection in the model described 
above.  Two key disadvantages of the model are that placement of the gastric cannulas 
requires general anaesthesia and surgical expertise and that total daily gastric acid output 
cannot be determined.  Although it has been argued that total daily gastric acid output may 
be a more sensitive marker of the effect of acid suppressive drugs [85], the clinical 
relevance of the it is not clear as intra-gastric pH, and specifically the percentage of time 
that pH exceeds 3 or 4 within each inter-treatment period are considered the primary 
determinants of efficacy for glandular and squamous disease, respectively, in humans 
[88]. 
As an alternative to the invasive, irreversible gastric cannulation models the 
placement of indwelling pH electrodes through the biopsy channel of an endoscope or 
nasogastric tube has been described [39,40,71,72,89].  Advantages of this model include 
its ease of use and the ability to study horses while they are fed or fasted.  However, a 
possible disadvantage of this model is that the presence of the tube in the oesophagus, 
pharynx and nostrils may affect eating behaviour, although anecdotally this does not 
appear to be a significant factor.  The use of mercury-weighted balloons to seat the probe 
ventrally has been described [70,71], but the exact location of the pH probe is unknown 
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and the use of mercury presents significant occupational health and safety concerns.  Due 
to the limitations of this technique its use has fallen out of favour.   
A final method for evaluating intra-gastric pH by aspirating gastric fluid during 
endoscopic examination has also been described [85,90–92]. The advantages of this 
technique are that is it simple, quick and easy to perform.  However, the technique 
requires fasting of the horse to collect a representative sample of fluid and is therefore 
potentially influenced by the same factors that influence the gastric cannulation fluid 
collection model, namely the potential for fasting to impact on drug bioavailability, the 
effect of the loss of feeding induced parietal cell stimulation and the potential for mixing of 
saliva and duodenal reflux to confound the results.  Further, the technique does not lend 
itself to the sequential measurement of intra-gastric pH over consecutive days.     
1.6 Justification for the Current Thesis 
As discussed above, despite its widespread use for over 20 years, the 
pharmacodynamics of omeprazole under clinically relevant conditions are poorly 
understood.  Further, the factors that affect pharmacodynamics and pharmacokinetics of 
omeprazole in the horse are poorly elucidated.  The recent recognition that EGGD lesions 
fail to heal at a rate comparable with ESGD lesions [8–10] has reinvigorated interest in the 
overall efficacy of omeprazole as a suppressor of gastric acidity in the horse.  Specifically, 
conflicting evidence in the current literature raises the question as to whether levels of acid 
suppression that are likely to result in EGGD healing are achieved under clinically relevant 
conditions.   Further, the expiration of the GastroGard® patent has resulted in an increased 
in the role of formulation as a number of generic formulations have been released onto the 
market.  Lastly, EGUS, and in particular EGGD, is becoming increasingly recognized in 
non-racehorse populations [31], many of which consume high roughage based diets, and 
the role of diet in the efficacy of omeprazole is becoming increasingly recognized as a 
potentially important factor. 
Given the potential impact of fasting to inadvertently increased the efficacy of the 
drug in the cannula/pentagastrin stimulation model used in many of the early studies 
investigating the efficacy of omeprazole in the horse, compared with the more clinically 
relevant conditions of the Merritt et al [11] study in 2003, the authors considered that re-
evaluation of the efficacy of omeprazole using a clinically relevant model was justified.  
This formed the cornerstone of the justification for the current thesis.  Further, given that 
the factors that potentially affect the efficacy of orally administered omeprazole including 
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formulation, dose and diet are poorly described a further justification for the thesis is to fill 
holes in the existing knowledge base related to these.  The aims of the current thesis were 
to investigate; 
- The role of formulation, diet and dose on the pharmacokinetics of 
omeprazole in the horse; 
- The role of diet and dose on the pharmacodynamics of omeprazole in the 
horse under clinically relevant conditions; 
- The feasibility of pharmacokinetic/pharmacodynamic modelling of 
omeprazole in the horse. 
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Chapter 2 - Pharmacokinetics of intravenous, plain oral and enteric-coated oral 
omeprazole in the horse. 
This chapter consists of a paper published as: 
Sykes BW, Underwood C, McGowan C, Mills P. C. Pharmacokinetics of 
intravenous, plain oral and enteric-coated oral omeprazole in the horse. J Vet 
Pharm Ther. 38,130-136 (2015). 
2.1 Prelude 
 It is generally recommended that omeprazole requires some form of protection 
because exposure to acid in the stomach followed by alkalinisation in the small intestine 
renders the drug inactive before absorption can occur [11].  However, the magnitudes of 
effect of different mechanisms of protection have been poorly described.  A bioavailability 
of 6 - 12% on day 1 of administration of enteric coated granules in a gelatine capsule has 
been previously reported, although blood levels of omeprazole were undetectable in 3/8 
horses in each of the studies [4,78] limiting the interpretation of such studies.  One of the 
reasons for the inability to detect blood levels of omeprazole despite an apparent acid 
suppressive effect that was observed concurrently is the relatively poor sensitivity of the 
analytical methods used in the earlier studies compared to modern analytical techniques. 
The objectives of this study were to; 
 Document the pharmacokinetics of intravenous, enteric-coated oral and plain 
(unprotected) oral omeprazole in fasted horses;  
 Investigate the impact of feeding on the bioavailability of an enteric-coated 
formulation of omeprazole.  
2.2 Abstract  
The objectives were to document the pharmacokinetics of intravenous, enteric-
coated oral and plain oral omeprazole in fasted horses, and to investigate the impact of 
feeding on the bioavailability of an enteric-coated omeprazole.  Twelve horses received 
four treatments: Intravenous (IV) omeprazole (0.5 mg/kg) in the fasted state (IV-Fasted), 
enteric-coated omeprazole (4 mg/kg) orally in the fasted state (ECO-Fasted), enteric-
coated omeprazole (4 mg/kg) orally in the fed state (ECO-Fed) and plain omeprazole (4 
mg/kg) orally in the fasted state (PL-Fasted).  Plasma omeprazole concentrations were 
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determined by Ultra High Performance Liquid Chromatography-Mass Spectrometry 
(UHPLC-MS). Bioavailability was higher (p=0.038) in the ECO-Fasted group (21.5 [9.0-
27.7] %) than the PL-Fasted group (10.1 [7.7-13.3] %).  Similarly AUC0-∞ was higher in the 
ECO-Fasted group than the PL-Fasted group (p=0.027).  No significant differences were 
present between the ECO-Fasted and ECO-Fed groups with regards to bioavailability, 
maximum plasma concentration (Cmax), Tmax or AUC0-∞. When the t1/2 data from the oral 
formulations was pooled it was longer than that observed in the IV-Fasted group (100 [73-
118] min) and 35 [34-39] min, respectively; p<0.0001).    The bioavailability of enteric-
coated omeprazole was higher than previously reported and feeding had minimal impact.  
Bioavailability of plain omeprazole was approximately half that of enteric-coated 
omeprazole.  The longer t1/2 observed following oral administration was consistent with the 
flip-flop effect and has not previously been described for omeprazole in the horse. 
2.3 Introduction 
Equine gastric ulcer syndrome (EGUS) remains a common condition of 
performance horses with omeprazole considered a cornerstone of therapy [93]. 
GastroGard®,  which utilises a highly alkaline medium to buffer and protect the omeprazole 
from degradation by gastric acidity [11], is the most thoroughly evaluated formulation and 
numerous studies have documented its efficacy at a dose of 4 mg/kg PO once daily in the 
treatment of EGUS [5–7,50,94,95].  Recently, enteric-coated omeprazole at a dose of 1 
mg/kg PO once daily has been demonstrated to be non-inferior to enteric-coated 
omeprazole administered at the reference dose (4 mg/kg PO once daily) [8] in the 
treatment of naturally occurring gastric ulceration in clinical patients.  This is in direct 
contrast to a similar study in which a lower dose (1.6 mg/kg PO once daily) of buffered 
omeprazole was inferior to the reference (4 mg/kg PO once daily) dose [10], suggesting 
that the bioavailability of enteric-coated formulations may be higher than buffered 
formulations, thereby allowing the use of lower doses with similar efficacy.    
An early study evaluating an enteric-coated formulation of omeprazole administered 
orally reported minimal pharmacokinetic data with undetectable serum concentrations in 
3/8 horses studied [4].  Utilising data from the five horses for which serum omeprazole 
concentrations were detectable, an oral bioavailability of 6 - 13 % was reported, with 
variable absorption resulting in omeprazole plasma AUC values varying by over 300% [4]. 
Another study reported undetectable serum concentrations in 3/8 horses, a similar wide 
variation in AUC [78] and a bioavailability of 12 – 14% in the remaining animals [78]. 
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Adequate acid suppression, as measured by the collection of gastric fluid through an 
indwelling percutaneous cannula in fasted horses, was observed in all horses [4,78].  The 
reasons for the failure to detect serum concentrations of omeprazole in some animals 
were not explained.    
The impact of feeding on the bioavailability of omeprazole in the horse is also poorly 
described.  One study evaluating a buffered formulation of omeprazole reported that fasted 
horses had a 300% greater AUC compared to fed horses administered the same dose [3].  
Given that AUC is the primary determinant of the magnitude and duration of acid 
suppression achieved following the administration of omeprazole in other species [66], this 
finding is potentially relevant in the clinical setting; yet no follow up studies have been 
performed to document the effect of feeding on the bioavailability.  Further, to the authors’ 
knowledge, the effect of feeding on the bioavailability of enteric-coated formulations has 
not been reported.   
It has been previously reported that omeprazole requires some form of protection 
because exposure to acid in the stomach followed by alkalinisation in the small intestine 
renders the drug inactive before absorption can occur [11].  However, a generic 
formulation of plain, unprotected omeprazole has recently been released onto the 
European market (Peptizole®, Norbrook, Co. Down, UK).  The use of an unprotected 
formulation conflicts with previous recommendations [11], but evaluation of the potential 
efficacy of this formulation is difficult as little published information on bioavailability of 
plain omeprazole is available. 
Considering this; the objectives of this study were: 1) to document the 
pharmacokinetics of intravenous, enteric-coated oral and plain (unprotected) oral 
omeprazole in fasted horses; and 2) to investigate the impact of feeding on the 
bioavailability of an enteric-coated formulation of omeprazole.   
2.4 Materials and Methods 
 The omeprazole for intravenous injection was sourced from a human compounding 
pharmacy (Think Pharmacy, Aspley, QLD, Australia) as a powdered USP grade 
omeprazole (99.8% purity). It was stored at 4oC, as per the manufacturer’s instructions, 
until reconstituted immediately prior to administration.  The plain omeprazole for oral 
administration was sourced from a commercial veterinary compounding pharmacy (BOVA 
Compounding, Sydney, NSW, Australia) as a paste formulation.  It consisted of uncoated 
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USP grade omeprazole (99.8% purity) formulated into a paste within an almond oil 
suspension at a concentration of 100 mg/mL.  Stability of the formulation was reported by 
the compounder as 3 months.  The enteric coated formulation (Gastrozol®) studied was a 
commercially available, 50 mg/mL paste formulation for oral administration.   
2.4.1 Animals & animal ethics  
Twelve healthy, adult, privately owned Thoroughbred horses (aged 5 – 15 years, 
406 – 606 kg BW) consisting of six male castrates and six females were used.  During the 
studies horses were housed in a 12 m2 stable bedded with wood shavings and fed as per 
the protocol for the allocated treatment (see below).  A washout period of at least 1 week 
separated the treatments during which time horses were allowed access to pasture 
supplemented by good quality alfalfa hay. 
The study was performed under an ethics permit from the New South Wales 
Department of Primary Industries (TRIM 12/4903). Informed consent from the owner, or 
the trainer acting as an agent for the owner, was obtained at the time of enrolment to the 
study. 
2.4.2 Group allocation and sequencing  
Each horse received four treatments: Intravenous omeprazole (0.5 mg/kg) in the 
fasted state (IV-Fasted), enteric-coated omeprazole (4 mg/kg) orally in the fasted state 
(ECO-Fasted), enteric-coated omeprazole (4 mg/kg) orally in the fed state (ECO-Fed) and 
plain (unprotected) omeprazole (4 mg/kg) orally in the fasted state (PL-Fasted).  Horses 
were blocked into groups of four animals with the horses within each block receiving all 
four treatments before being replaced by the subsequent block of four horses in an all-
in/all-out manner.  To accommodate the effect of time, the four horses within each block 
were randomized on week 1 into one of the four treatment groups and subsequently 
managed in a cross-over design such that each treatment was administered to a single 
horse each week.   
The omeprazole for intravenous use was reconstituted with 2.25 mmol/L NaOH in 
sterile water to a concentration of 5 mg/mL. The solution was administered through a 0.2 
µm filter (Minisart®, Sartorius, Dandenong Sth, VIC, Australia) within 15 min of 
reconstitution, and over a period of 5 min, as previously described [74].   
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To ensure accurate dosing each horse was weighed on electronic scales 
(Accuweigh Equestrian Scales®, Accuweigh, Willeton, WA, Australia) the day prior to each 
investigation.  For three of the investigations (IV-Fasted, ECO-Fasted, PL-Fasted) the 
horses were fasted for 16 hours to ensure adequate emptying of the stomach [93].  For the 
fourth investigation (ECO-Fed) horses were allowed access to free-choice alfalfa hay 
before and during the study period. Fresh water was available at all times.  An IV catheter 
was placed on the morning of testing approximately 1 hour prior to the administration of 
the omeprazole to allow collection of the blood samples.  When the investigation involved 
IV omeprazole catheter placement was repeated on the opposite jugular vein to facilitate 
administration of the drug.  The catheter was removed immediately following 
administration of omeprazole.   
A pre-administration blood sample was collected, the omeprazole administered and 
further blood samples collected from the catheter at T= 2 (IV only), 5 (IV only), 10, 20, 30, 
40, 50, 60, 70, 80, 90, 100, 110, 120, 135 min and 2.5, 3, 3.5, 4, 5, 6, 9 and 12 hours.  Ten 
mL of blood was collected on each occasion with 4 mL transferred to a lithium heparin 
tube (Vacutainer®, BD, North Ryde, NSW, Australia). The samples were separated by 
centrifugation at 3,500 g for 10 min immediately following collection and the plasma frozen 
(-20 oC) within 30 min of collection.    
2.4.3 Sample extraction  
A protein precipitation extraction was performed; 50 µL of the sample was added to 
a 1.5 mL Eppendorf tube and 150 μL of a methanol: acetone mix at a ratio of 80:20 was 
added. The solution was then mixed by vortexing for 15 seconds, followed by 
centrifugation of the mixture at 15,000 g for 10 min. The supernatant was collected for 
UHPLC-MS analysis. Recovery of omeprazole for the extraction method was >95%. 
2.4.4 Determination of plasma omeprazole concentration  
A Nexera UHPLC coupled with LCMS-8030 triple quadruple mass spectrometer 
(Shimadzu Corporation, Tokyo, Japan) operating in positive electrospray ionization (ESI) 
mode was used for analysis with a reverse phase C18 column (Kinetex 1.7µ XB-c18 100A, 
size 50 × 2.1mm, Phenomenex, North Ryde, Australia) employed; the injection volume 
was 5 µL. The mobile phase consisted of Solvent A (10 mmol/L ammonium formate) and 
Solvent B (acetonitrile) in the following program: a gradient run of 40% B to 60% B for 1 
min, a 0.1 min to 95% B and held for 1 min and then run at 5% B in an isocratic mode for 1 
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min. The flow rate was maintained at 0.4 mL min-1 at temperature of 40 °C. The drying gas 
was at 250 °C, the gas flow at 15 L/min, the nebulizing gas flow at 3 L/min, and the heating 
block at 400 °C. Nitrogen was used as the drying and nebulizing gas and the capillary 
voltage was 4.5 KV. Using direct flow injection analysis the omeprazole was optimized for 
solvent extraction in a positive mode with a MRM scan of precursor ion 346.2 and its 
product ion of 198.0. The dwell time was 50 ms for all.  The chromatography method was 
validated by the manufacturer (Shimadzu Corporation, Sydney, NSW, Australia) using a 
stock standard of omeprazole diluted in acetonitrile with a lower limit of quantification of 
0.001 μg/mL and a relative standard deviation of < 3% for AUC and drug concentration 
reported.      
A calibration curve was prepared from a stock standard of omeprazole diluted in 
acetonitrile at 20 μg/mL with serial four fold dilutions performed using a methanol: acetone 
mix at a ratio of 80:20. The final calibration curve concentrations were 5, 1.25, 0.3125, 
0.07812 and 0.019 μg/mL.  Samples of each calibration curve concentration were frozen at 
-20 oC.  To adjust for variability in conditions between runs, the same stock calibration 
curve solutions were used throughout. A 50 μL aliquot of each calibration curve 
concentration was allowed to warm to room temperature and then transferred to a 200 μL 
sampling tube for analysis.  Calibration points were performed on three occasions (the 
beginning, middle and end) of each run.  All data points were manually examined for 
validity as determined by the appearance of the chromatograph with valid data points, 
including the repeated samples for the calibration, then processed using the UHPLC post-
run analysis software (Lab Solutions, Shimadzu Corporation, Tokyo, Japan) allowing 
correction for intra-run variability. Unknown samples were run in batches of 80-90 with a 
total run time of approximately 6 hours.  The magnitude of intra-run variability was 
determined by calculating the coefficient of variation of the values for the replicates of the 
calibration curve samples determined at the beginning, middle and end of each run.  Inter-
run variability was determined by calculating the coefficient of variation between runs for 
each calibration point using average values within each run.  Accuracy of the analysis was 
determined by calculating the coefficient of determination for the calibration curve using 
Microsoft Excel®'s (Microsoft, Redmont, WA, USA) graphing function. 
2.4.5 Pharmacokinetic evaluation  
The pharmacokinetic calculations were carried out by non-compartmental 
assessment of the data using an open source pharmacokinetic program (PK Solver, China 
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Pharmaceutical University, Niinjing, China) [96]. Maximum plasma concentration (Cmax) 
and Tmax were directly calculated from the data.  The elimination rate constant (lambda-z) 
was estimated by log-linear regression of concentrations observed during the linear phase 
of elimination, and the corresponding elimination t1/2 calculated as 0.693/lambda-z. The 
AUC vs. time curve (AUC0–∞) was calculated using the linear trapezoidal rule and oral F% 
calculated from the ratio of the AUC, after oral and IV administration, indexed to their 
respective dose: 
F (%) = ((AUCPO × DoseIV)/(AUCIV × DosePO)) × 100  
2.4.6 Data analysis  
Data were analysed using GraphPad Prism® (GraphPad Software, La Jolla, CA, 
USA). The data were tested for normality using D’Agostino-Pearson omnibus K2 normality 
tests. The majority of data was non-Gaussian, so non-parametric statistical tests were 
used throughout. Oral F%, Cmax, Tmax and AUC0–∞ in ECO-fasted horses were compared to 
those in ECO-fed horses and PL-fasted horses using a Friedman test with Dunn’s multiple 
comparisons. Data from the oral formulations was pooled and the t1/2 for the oral 
formulations was compared to that for the IV-Fasted group using a Mann-Whitney U test.  
Data are presented as median (interquartile ranges (IQR)). Significance was set at 
P<0.05. 
2.5 Results 
All horses successfully completed the study.  A single adverse event was recorded 
with one dose of intravenous omeprazole accidently administered perivascularly (horse 5).  
No ill effects were observed as a result of the perivascular injection and the horse 
remained in the study.  Due to the loss of the IV data set from horse 5, pharmacokinetic 
data for IV administration was available for only 11 horses.  One horse (horse 2) 
demonstrated poor goodness of fit after subjective evaluation of the ECO-Fed data. Hence 
this horse was considered an outlier and was removed from comparisons between ECO-
fed and ECO-fasted groups.   
Intra-run variability, as determined by the relative standard deviation of replicate 
calibration curve samples within each run, was < 1% for all runs.  Inter-run variability, as 
determined by the relative standard deviation of average intra-run values for each 
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calibration point, ranged from 5 - 14%. The coefficient of determination (R2) for the 
calibration curve exceeded 0.99 for all runs. 
 The pharmacokinetics of omeprazole for the IV-Fasted group are summarized in 
table 2.1.  Table 2.2 summarizes the pharmacokinetics for the ECO-Fasted, ECO-Fed and 
PL-Fasted groups.  Median (IQR) plasma concentrations over time for the IV-Fasted, 
ECO-Fasted, ECO-Fed and PL-Fasted, groups are shown in figures 2.1 – 2.4, 
respectively.  
The bioavailability of oral formulations is shown in table 2.3.  Bioavailability was 
higher (p=0.038) in the ECO-Fasted group (21.5 [9.0-27.7] %) than the PL-Fasted group 
(10.1 [7.7-13.3] %).  Similarly AUC0-∞ was higher in the ECO-Fasted group than the PL-
Fasted group (p=0.027).  Cmax did not differ between the ECO-Fasted and PL-fasted 
groups (p=0.73).  No differences were present between the ECO-Fasted and ECO-Fed 
groups with regards to bioavailability, Cmax, Tmax or AUC0-∞.  Data from the oral 
formulations was pooled and the t1/2 for the oral formulations (99.73 min [72.5-117.6]) was 
longer (p<0.0001) than the IV-Fasted group (35.5 min [33.4-39.1]). 
2.6 Discussion 
The findings following intravenous administration are consistent with a previous 
report wherein omeprazole has been described as having elimination half-life of 
approximately  30 min [74].    The longer half-life observed following oral administration is 
consistent with the flip-flop effect [97] and has not previously been described for 
omeprazole in the horse.  The flip-flop effect primarily occurs in drugs that have a short 
half-life following intravenous administration.  It occurs when the rate of absorption 
following extra-vascular administration becomes the predominant determinant of plasma 
concentrations, rather than the rate of elimination, as ongoing absorption of the drug 
interferes with the calculation of clearance and determination of half-life [97]. As such, the 
reported half-life following extra-vascular, in this case oral, should not be misinterpreted as 
a measure of drug clearance [97].   
The bioavailability of the enteric-coated formulation examined in this study was 
higher than previously reported.  In two previous studies evaluating bioavailability of an 
enteric-coated formulation serum concentrations of omeprazole were not detectable in 
6/16 horses studied and in horses where the drug was detected an oral bioavailability of 6 
– 14% was reported [4,78].  One likely reason for the discrepancy between the previous 
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and present studies is the method of analysis used.  The older studies were performed 
over 20 years ago and the inability to detect omeprazole in serum despite adequate acid 
suppression in the horses [4,78] suggests that the limits of detection and/or the 
methodology used in the previous studies were much less sensitive than what is currently 
available.  This is likely to significantly impact on the determination of AUC, which is 
primarily used to calculate bioavailability.  Another factor that warrants consideration is the 
effect of formulation and the possibility that the formulation in the present study had 
superior bioavailability to that previously studied.  The formulation previously studied was a 
preparation of enteric-coated granules encapsulated in gelatine formulated for human use 
[4,78], whereas the formulation in the current study consists of enteric-coated granules 
suspended into paste that is specifically formulated for use in horses. Direct comparison 
between formulations is needed before any conclusions regarding the effect of different 
formulations on bioavailability can be drawn. 
The impact of feeding on the bioavailability of the enteric-coated formulation was 
minimal.  This is in direct contrast to that previously reported for a buffered formulation of 
omeprazole where fasted horses had a 300% greater AUC [3].  Given that AUC is the 
primary determinant of the magnitude and duration of acid suppression achieved following 
omeprazole administration [66], the previous study reporting that feeding has a large 
impact the bioavailability of buffered formulations [3] suggests that there may be a 
significant impact of feeding on the efficacy of buffered formulations of omeprazole.  This 
comment should be observed with caution as the previous study measured only a single 
time-point [3], but would still suggest that the effect of feeding on bioavailability may be 
partly dependent on formulation.  As such, caution should be exercised in extrapolating the 
results of the present study to different formulations and further work is needed to define 
the interactions present between feeding, formulation and bioavailability. 
A large degree of individual variation was observed with bioavailability in the ECO-
Fasted group ranging from 7% to 56%.  Three of the eleven horses for which bioavailability 
data was available appeared to absorb omeprazole poorly regardless of formulation or 
condition studied.  In humans, variation in the efficacy of omeprazole has been reported 
and is primarily related to mutations in the CYP2C19 gene and changes in the rate of 
elimination [98].  Whether the poor bioavailability observed in these horses reflects 
increased clearance, as observed in humans, is unclear as the half-life following 
intravenous administration in the three horses with the lowest bioavailability represented a 
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wide range of values (26.4, 48.1 and 39.1 min for horses 2, 9 and 10, respectively) as 
shown in table 3.  Alternatively factors that affect the rate of absorption may be important.  
Regardless of the underlying reason, the finding that some animals in the current 
study repeatedly achieved only low plasma concentrations of omeprazole following oral 
administration is interesting.  It potentially explains why healing of the squamous mucosa 
in only 70-85% of animals has consistently been observed in clinical trials [5–7,49,50] 
including one using the enteric coated formulation evaluated in the present study [8].  
Healing of the squamous mucosa should readily occur if adequate acid suppression is 
achieved and it is tempting to speculate that horses that absorb omeprazole poorly may be 
less likely to respond clinically.  Further work into the population pharmacokinetics of 
omeprazole and their impact on healing are justified.   
The bioavailability of the plain omeprazole studied was approximately half that of 
the enteric-coated formulation.  The median bioavailability of 10% was similar to that 
reported (10.5%) by the manufacturer of a generic plain omeprazole recently registered in 
the United Kingdom (Peptizole®) [99], although a  greater range was observed in the 
present study (4-21% vs. 4-13% as reported by the manufacturer [99]). However, caution 
should be exercised in drawing direct comparisons between the formulation studied and 
the registered formulation as differences in the composition, purity, potency and stability 
are likely to exist. 
The effect of feeding on the bioavailability of plain omeprazole was not investigated 
in the present study. At the time of study planning and execution buffered and enteric-
coated formulations were the only forms commercially available.  Accordingly, the primary 
objective of the study was to document the pharmacokinetics of enteric-coated 
omeprazole under different conditions as this was considered to be the most clinically 
relevant.  The inclusion of plain omeprazole administered to fasted horses was intended to 
partially fill the void in the literature and to provide preliminary information for future 
studies.  Further studies investigating the impact of feeding on the bioavailability of plain 
omeprazole would be beneficial in determining appropriate dosing strategies for that 
formulation. 
In conclusion, the findings of the present study are similar to previous reports 
regarding the pharmacokinetics of intravenous omeprazole.  In contrast, bioavailability of 
the enteric-coated formulation studied appears higher than previously reported and 
approximately twice that of plain omeprazole.  Further work into comparative 
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bioavailability, the effects of feeding and the role of individual variability in therapeutic 
response are required.
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Table 2.1 - Key pharmacokinetic parameters following administration of 0.5 mg/kg omeprazole intravenously. 
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Table 2.2 - Key pharmacokinetic parameters following administration of 4 mg/kg of enteric-coated omeprazole to fasted horses (ECO-
Fasted), enteric-coated omeprazole to fed horses (ECO-Fed) and plain omeprazole to fasted horses (PL-Fasted). 
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Table 2.3 - Bioavailability of enteric-coated omeprazole in fasted (ECO-Fasted) and fed 
(ECO-Fed) horses and plain omeprazole in fasted (PL-Fasted) horses. 
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Figure 2.1 - Plasma omeprazole concentrations following the administration of 0.5 mg/kg intravenously to 11 horses (IV-Fasted group). 
Data presented as median [IQR]. 
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Figure 2.2 - Plasma omeprazole concentrations following the administration of 4 mg/kg of enteric-coated omeprazole to 12 fasted horses 
(ECO-Fasted group). Data presented as median [IQR]. 
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Figure 2.3 - Plasma omeprazole concentrations following the administration of 4 mg/kg of enteric-coated omeprazole to 11 fed horses 
(ECO-Fed group). Data presented as median [IQR]. 
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Figure 2.4 - Plasma omeprazole concentrations following the administration of 4 mg/kg of plain omeprazole to 12 fasted horses (PL-
Fasted group). Data presented as median [IQR]. 
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Chapter 3 - The effect of feeding on the pharmacokinetic variables of two 
commercially available formulations of omeprazole. 
This chapter consists of a paper published as a short communication: 
Sykes BW, Underwood C, McGowan C, Mills P. C. The effect of feeding on the 
pharmacokinetic variables of two commercially available formulations of 
omeprazole.  J Vet Pharm Ther. 38, 500-503 (2015). 
3.1 Prelude 
 An early study evaluating the pharmacokinetics of a buffered formulation of 
omeprazole reported that fasted horses had a 300% greater AUC compared to fed horses 
administered the same dose [3].  This is in contrast to the findings of the first study in the 
current thesis (reported in chapter 2) wherein feeding did not affect the bioavailability of on 
an enteric coated formulations of omeprazole.  The contrast between these findings 
suggests that the impact of feeding on bioavailability may be, at least in part, dependent 
on the method of protection used.   
 Considering this the objectives of this study were; 
 To investigate the impact of formulation (enteric coated and buffered) and feeding 
on pharmacokinetic variables associated with the oral administration of omeprazole 
in the horse. 
3.2 Abstract 
The objectives of this study were to investigate the impact of formulation (enteric 
coated and buffered) and feeding on pharmacokinetic variables associated with the oral 
administration of omeprazole in the horse.  Six Thoroughbred racehorses were studied in 
a cross-over design.  Each received 2 g of an enteric coated or buffered formulation in 
both the fed and fasted state.  Plasma omeprazole concentrations were determined by 
UHPLC-MS.   The effects of feeding or formulation on AUC0-inf_obs, t1/2, Tmax or Cmax were 
not statistically significant.  However, a wider than expected degree of variation was 
present and examination of the raw data suggests that an effect of feeding, wherein the 
bioavailability of omeprazole may be reduced in the fed animal, may be present.  Further 
investigation in a larger population of animals to assess the factors that contribute to the 
wide degree of absorption observed is warranted. 
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3.3 Introduction 
Omeprazole is widely used for the treatment of gastric ulceration in the horse.  
Despite its widespread use, little has been published on factors that affect the absorption 
of oral formulations of omeprazole to date, including the effect of feeding.  An early study 
investigating the pharmacokinetics of a buffered formulation reported that, based on total 
AUC,  feeding resulted in apparent decrease in absorption to one-third of the levels 
observed in fasted animals [3]. However, this study was complicated in that the horses in 
the fasted state had already received five doses of omeprazole, and were compared to 
horses in the fed state after their first and fourteenth doses [3]. In contrast, a recent study 
investigating the pharmacokinetics of a single dose of an enteric coated formulation of 
omeprazole reported that absorption in fed animals was not significantly reduced 
compared to fasted animals [100].  These findings suggested that the effect of feeding 
may be, at least in part, dependent on the formulation used.  If present, such an effect 
would have significant implications for the dosing of different formulations of omeprazole 
under different clinical conditions.  The objectives of this study were therefore to 
investigate the impact of formulation (enteric coated and buffered) and feeding on 
pharmacokinetic variables associated with the oral administration of omeprazole in the 
horse. 
3.4 Materials and Methods  
3.4.1 Animals & animal ethics 
Six healthy, adult, privately owned Thoroughbred horses (aged 4 – 8 years, 455 - 
510 kg BW) consisting of three male castrates and three females were used.  During the 
studies horses were housed in a 12 m2 stable bedded with wood shavings and fed as per 
the protocol for the allocated treatment (see below).  The study was performed under an 
ethics permit from the New South Wales Department of Primary Industries (TRIM 14/836). 
Informed consent from the owner, or the trainer acting as an agent for the owner, was 
obtained at the time of enrolment to the study. 
3.4.2 Group allocation and sequencing 
Each horse received four treatments: Enteric coated – Fasted (ECO-Fasted), 
Enteric coated – Fed (ECO-Fed), Buffered – Fasted (BUFF – Fasted) and Buffered – Fed 
(BUFF – Fed).  The formulations studied were chosen as they are the two leading selling 
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brands in Australia.  Both formulations are registered for use in horses in Australia.  The 
enteric coated formulation (Gastrozol®) studied was a 50 mg/mL paste formulation for oral 
administration.  The buffered formulation (Omoguard®, CEVA, Glenorie, NSW, Australia) 
studied was a 370 mg/g paste formulation for oral administration.  Horses were 
administered a total dose of 2 g (equivalent to 4 mg/kg for a 500 kg animal) in each 
treatment of the trial.  A total dose was chosen over an individualized mg/kg dose as the 
presentation of one of the formulations precluded accurate fine tuning of the dose.  Each 
horse received a different medication each week in a cross-over study.  Based on a 
previously reported half-life following intravenous administration of approximately 30 
minutes [74,100] a washout period of at least 1 week separated the treatments. Further, 
previous studies have documented that prior administration of the drug does not affect the 
pharmacokinetics of subsequent doses in the horse [3]. During the washout period horses 
were allowed access to pasture supplemented by good quality alfalfa hay. 
Each horse was weighed on electronic scales (Accuweigh Equestrian Scales®) the 
day prior to each investigation and the amount of supplemental hay fed adjusted to ensure 
that the maximal deviation from their baseline bodyweight was ± 5 %.  For two of the 
investigations (ECO-Fasted, and BUFF-Fasted) the horses were fasted for 16 hours to 
ensure adequate emptying of the stomach [93].  For the other two investigations (ECO-
Fed and BUFF-Fed) horses were allowed access to free-choice alfalfa hay before and 
during the study period. Fresh water was available at all times.  An IV catheter was placed 
on the morning of testing approximately 1 hour prior to the administration of the 
omeprazole to allow collection of the blood samples.     
A pre-administration blood sample was collected, the omeprazole administered and 
further blood samples collected from the catheter at T = 15, 30, 45, 60, 75, 90, 105, 120 
min and 2.5, 3, 3.5, 4, 5, 6 and 9 hours.  Ten mL of blood was collected on each occasion 
with 4 mL transferred to a lithium heparin tube (Vacutainer®). The samples were separated 
by centrifugation at 3,500 g for 10 min immediately following collection and the plasma 
frozen (-20 oC) within 30 min of collection.   Samples were processed within 6 weeks of 
collection and all analysis was completed within a 1 week period. 
3.4.3 Sample extraction and determination of plasma omeprazole concentration 
Sample extraction was performed using protein precipitation extraction and plasma 
omeprazole concentration was determined by UHPLC-MS analysis as recently described 
[100].  The magnitude of intra-run variability was determined by calculating the coefficient 
66 
 
of variation of the values for the replicates of the calibration curve samples determined at 
the beginning, middle and end of each run.  Inter-run variability was determined by 
calculating the coefficient of variation between runs for each calibration point using 
average values within each run.  Accuracy of the analysis was determined by calculating 
the coefficient of determination for the calibration curve using Microsoft Excel®'s graphing 
function.   
3.4.4 Pharmacokinetic evaluation 
The pharmacokinetic calculations were carried out by non-compartmental 
assessment of the data using an open source pharmacokinetic program (PK Solver) [96]. 
Maximum plasma concentration (Cmax) and Tmax were taken directly from the observed 
data.  The elimination rate constant (lambda-z) was estimated by log-linear regression of 
concentrations observed during the linear phase of elimination, using a minimum of three 
data points automatically selected by the program and confirmed by visual examination of 
the plotted data.  The corresponding elimination t1/2 was calculated as 0.693/lambda-z. 
The AUC vs. time curve (AUC0–∞) was calculated using the linear trapezoidal rule.  
3.4.5 Data analysis 
Data were analysed using GraphPad Prism® and R/R Commander® (McMaster 
University, Hamilton, ON, Canada). The data were tested for normality using D’Agostino-
Pearson omnibus K2 normality tests. The data was non-Gaussian so it was log 
transformed then analysed. A preliminary ANOVA was performed to assess whether order 
of drug administration had an effect on any of the variables tested (Tmax, Cmax and AUC0-∞). 
A two-way repeated measures ANOVA with Sidak’s multiple comparisons test was then 
performed with feeding (fed vs. fasted) and formulation (ECO vs. BUFF) as factors for 
each variable. Significance was set at P<0.05. A power calculation was performed based 
on the previously reported difference between fed and fasted states of 300% [3] and 
suggested that 6 horses would provide a power of >80% to detect a difference between 
the groups. 
3.5 Results  
All horses successfully completed the study.   Median intra-run variability, was 3.2% 
[IQR: 0.7 – 12.5%].  Median inter-run variability was 3.2% [IQR: 1.5 – 6.5%]. The median 
coefficient of determination (R2) for the calibration curves was > 0.99 [IQR: 0.96 – >0.99].  
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The key pharmacokinetic parameters for the four conditions studied are shown in table 
3.1.  Median (IQR) plasma concentrations over time for the ECO-Fasted, BUFF-Fasted, 
ECO-Fed and BUFF-Fed groups are shown in figures 3.1 – 3.4 respectively. When 
assessed visually both formulation and feeding appeared to influence the pharmacokinetic 
behaviour of the drug however, there was no statistically significant effect of feeding or 
formulation on AUC0-α, t1/2, Tmax or Cmax. There was no effect of order of drug 
administration on any of the variables tested (Tmax, Cmax and AUC0-∞). 
3.6 Discussion  
The results of the present study suggest that the effects of feeding on the 
absorption of an orally administered buffered formulation of omeprazole are less than 
previously described [3].  The magnitude of the effect observed for the enteric coated 
formulation is similar to a recent report [100].  
No statistically significant differences were observed between the fed and fasted 
states for either formulation.  However, examination of the raw data, in particular AUC0–∞, 
suggests that an effect may be present but that a wide degree of variation is present.  The 
magnitude of variation was greater than anticipated and consequently the power of the 
study to detect a difference between the groups was reduced.  Considering this; the 
authors propose that, although not statistically significant, the results of this preliminary 
study justify further investigation into the potential effects of feeding on the 
pharmacokinetics of different formulations of omeprazole in larger populations of animals. 
The wide degree of variation observed in bioavailability suggests that the investigation of 
population pharmacodynamic modelling is warranted. 
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Table 3.1 – Key pharmacokinetic parameters of omeprazole following the administration of 2 g of either an enteric coated (ECO) or 
buffered (BUFF) formulation of omeprazole orally in the fed and fasted state to six horses.  
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Figure 3.1 - Median (IQR) serum concentrations over time for omeprazole following the administration of 2 g of an enteric coated 
formulation of omeprazole to six fasted horses. 
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Figure 3.2 - Median (IQR) serum concentrations over time for omeprazole following the administration of 2 g of a buffered formulation of 
omeprazole to six fasted horses. 
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Figure 3.3 - Median (IQR) serum concentrations over time for omeprazole following the administration of 2 g of an enteric coated 
formulation of omeprazole to six fed horses. 
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Figure 3.4 - Median (IQR) serum concentrations over time for omeprazole following the administration of 2 g of a buffered formulation of 
omeprazole to six fed horses. 
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Chapter 4 - Pharmacokinetics and bioequivalence testing of five commercial 
formulations of omeprazole in the horse. 
This chapter consists of a paper published as: 
Sykes BW, Underwood C, McGowan C, Greer, R. Mills P. C. Pharmacokinetics and 
bioequivalence testing of five commercial formulations of omeprazole in the horse  J 
Vet Pharm Ther. 39, 78-83 (2016). 
4.1 Prelude  
 To date little work has been done on the comparative pharmacokinetics of different 
formulations of omeprazole in the horse.  The findings of first study of this thesis (as 
reported in chapter 2) supported the recommendation that omeprazole be protected in 
some form to prevent degradation by gastric acidity.  However, little is known on the 
relative efficacy of different mechanism of protection, namely buffered pastes versus 
enteric coated formulations.  A recent study no difference between the pharmacokinetics 
of a buffered formulation (GastroGard®) and an enteric coated formulation (Gastrozol®) 
although the doses used in this study were not identical.  As such drawing firm conclusions 
is not possible as dose linear pharmacokinetics have not been demonstrated in the horse. 
 Considering this the objectives of the study were to; 
 To investigate the relative pharmacokinetics of five commercially available 
formulations of omeprazole in the horse; 
 To test for bioequivalence of four of the formulations against a reference 
formulation (GastroGard®). 
4.2 Abstract  
Omeprazole is widely used in the treatment of equine gastric ulcer syndrome.  To 
date, little is known about the relative pharmacokinetics of the different formulations 
making comparisons between products difficult.  The objectives of the study were to 
investigate the relative pharmacokinetics of five commercially available formulations of 
omeprazole in the horse, and to test for bioequivalence of four of the formulations using 
one of the formulations as a reference standard.    Twelve mature Thoroughbred horses 
were fasted for 16 hours then administered 2 g of each formulation in a cross-over design. 
Serial blood samples were collected and plasma omeprazole concentration was 
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determined by UPLC-MS.  No significant differences were present between three of the 
formulations and the reference formulation, while the fourth formulation had a lower Cmax 
and longer Tmax than the reference formulation.  Bioequivalence against the reference 
formulation could not be demonstrated for any of the formulations tested. The findings of 
the study suggested that the method of protection utilised by different formulations of 
omeprazole (enteric coated granules vs. buffering) does not significantly alter the 
pharmacokinetics of the drug.  Further work to establish bioequivalence is needed before 
direct comparisons can be drawn between different formulations.   
4.3 Introduction 
Omeprazole is widely used in the treatment of EGUS.  It has been previously 
recommended that omeprazole requires some form of protection because exposure to 
acid in the stomach followed by alkalinisation in the small intestine renders the drug 
inactive before absorption can occur [11].  As such, commercial formulations of the drug 
typically incorporate some form of protection such as buffering with a highly alkaline 
medium, or the use of enteric coated granules suspended in a paste.    A recent study 
reported the bioavailability of an enteric coated granule formulation (Gastrozol®) to be 
approximately twice that of a compounded, plain, unprotected omeprazole [100] 
supporting this recommendation.   
The efficacies of the different methods of protection are, however, poorly 
investigated to date.  A recent study compared the bioavailability of GastroGard®, which 
utilises a highly alkaline medium to buffer the omeprazole, to Gastrozol®, a formulation 
containing enteric coated granules suspended in a paste [69]. In that study, no difference 
in endoscopic healing of lesions was observed and the bioavailability of Gastrozol® was 
1.26 times higher than GastroGard®, although the difference was not statistically 
significant as a wide 95% confidence interval (95% CI: 0.56 – 2.81) was present [69].  
However, interpretation of the results was difficult as the dose of omeprazole used for 
GastroGard® of 4 mg/kg PO once daily differed from the dose of 1 mg/kg PO once daily 
used for Gastrozol®. Yet, to the authors’ knowledge, dose linear pharmacokinetics have 
not been demonstrated for omeprazole in the horse; it cannot be assumed that the 
pharmacokinetics of the two doses are equivalent, and the direct comparison of different 
doses is not appropriate.    
Considering the current lack of information on the efficacy of methods of protection 
the primary objective of this study was to investigate the relative pharmacokinetics of five 
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commercially available formulations of omeprazole in the horse.  A second objective of the 
study was testing for bioequivalence of four of the formulations against a reference 
formulation (GastroGard®). 
4.4 Material and Methods 
 Five commercially available formulations of omeprazole were studied.  GastroGard
®
 
was used as the reference formulation.  Two buffered formulations, Omoguard® and 
Abgard® (Abler, Vanuatu), and two enteric coated granule formulations, Gastrozol® and 
BOVA Omeprazole Granules (BOVA Compounding, Caringbah, NSW, Australia) were 
used as comparison formulations. Details of the formulations including the method of 
protection utilised and concentration are shown in table 4.1.  
GastroGard® was chosen as the reference formulation due to extensive evaluation 
with numerous studies documenting its efficacy in the treatment of squamous gastric 
ulceration at a dose of 4 mg/kg PO once daily [5–7,50,94,95]. The remaining formulations 
were chosen because of their availability commercially in either Australia (Gastrozol®, 
Omoguard®, BOVA Omeprazole Granules) or the Middle East (Abgard®). Where the 
formulations were not available in Australia (GastroGard® and Abgard®), they were 
imported on an APVMA special use permit.  
4.4.1 Animals and animal ethics 
 Twelve healthy, adult, privately owned Thoroughbred horses (aged 3–13 years, 
460–588 kg bodyweight (BW) consisting of six male castrates and six females were used. 
During the studies, horses were housed in a 12 m2 stable bedded with wood shavings.  
Based on a previously reported t1/2 of approximately 30 min following IV administration 
[74,100], a washout period of at least 1 week separated the treatments during which time 
horses were allowed access to pasture supplemented by good quality alfalfa hay.  
The study was performed under an ethics permit from the New South Wales 
Department of Primary Industries (TRIM 13/1125). Informed consent from the owner, or 
the trainer acting as an agent for the owner, was obtained at the time of enrolment to the 
study. 
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4.4.2 Group allocation and sample collection 
 Horses were blocked into two groups of six animals.  The six horses within each 
block were randomised on week 1 with five of the horses receiving one of the medications 
and the sixth horse receiving no medication.  The horses were subsequently managed in a 
cross-over design such that each treatment was administered to a single horse each week 
and one horse received no medication.  At the completion of the six week studied period 
each horse had received one medication per week for five of the weeks and no medication 
in one of the weeks.  The original six horses were then replaced by the subsequent block 
of six horses in an all-in/all-out manner 
 The presentation of two of the formulations (Omoguard® and Abgard®) was not 
conducive to dose titration on an mg/kg basis.  Instead each formulation was administered 
at a total dose of 2 g (equivalent to 4 mg/kg for a 500 kg horse) orally.  To minimise week 
to week variation in BW, each horse was weighed on electronic scales (Accuweigh 
Equestrian Scales®) on a weekly basis and the amount of supplemental hay fed adjusted 
to ensure that the maximal deviation from their baseline BW was ± 5 %.   
 For all of the investigations the horses were fasted for 16 hours to ensure 
adequate emptying of the stomach [93].  Fresh water was available at all times.  An IV 
catheter was placed on the morning of testing approximately 1 hour prior to the 
administration of the omeprazole to allow collection of the blood samples.  A pre-
administration blood sample was collected, the omeprazole administered and further blood 
samples collected from the catheter at T= 15, 30, 45, 60, 75, 90, 105 min and 2, 2.5, 3, 
3.5, 4, 5, 6 and 8 hours.  Ten mL of blood was collected on each occasion with 4 mL 
transferred to a lithium heparin tube (Vacutainer®). The samples were separated by 
centrifugation at 3,500 g for 10 min immediately following collection and the plasma frozen 
(-20 oC) within 30 min of collection.  
4.4.3 Sample extraction and determination of plasma omeprazole concentration  
Sample extraction was performed using protein precipitation extraction and plasma 
omeprazole concentration was determined by UHPLC-MS analysis as recently described 
[100].  The magnitude of intra-run variability was determined by calculating the coefficient 
of variation of the values for the replicates of the calibration curve samples determined at 
the beginning, middle and end of each run.  Inter-run variability was determined by 
calculating the coefficient of variation between runs for each calibration point using 
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average values within each run.  Accuracy of the analysis was determined by calculating 
the coefficient of determination for the calibration curve using Microsoft Excel®'s graphing 
function. 
4.4.4 Pharmacokinetic evaluation 
 The pharmacokinetic calculations were carried out by non-compartmental 
assessment of the data using an open source pharmacokinetic program (PK Solver) [96]. 
Maximum plasma concentration (Cmax) and Tmax were directly calculated from the data by 
the software program.  The elimination rate constant (lambda-z) was estimated by log-
linear regression of concentrations observed during the linear phase of elimination, using 
at least three data points automatically selected by the program and confirmed by visual 
examination of the plotted data.  The AUC vs. time curve (AUC0–∞) was calculated using 
the linear trapezoidal rule.  
4.4.5 Data analysis 
 Data were analysed using a computer software program (R/R Commander®). Data 
was assessed for normality using the D’Agostino-Pearson omnibus normality test.  The 
data was non-parametric and was log-transformed to allow parametric analyses.  The 
effect of order of administration (before vs. after reference formulation) was evaluated 
using t-tests. A Bonferroni correction was applied to account for multiple comparisons. A 
repeated measures ANOVA with Dunnett’s post-test was performed to compare the AUC0-
∞, Cmax and Tmax of the reference formulation (GastroGard
®
) versus the comparison 
formulations. Significance was set at P≤0.05. Summary statistics are expressed as mean 
(± SD) or geometric mean with corresponding 95% confidence intervals. Inter- and intra-
run variabilities are reported as median [IQR]. 
Bioequivalence was calculated as per the committee for veterinary medicinal 
products guidelines for the conduct of bioequivalence studies for veterinary medicinal 
products [101]; for the comparison compound to be considered bioequivalent to the 
reference formulation (GastroGard®) the back-transformed 90% confidence interval for the 
ratio of the two treatment means must be contained within the limits 0.8-1.25.  For each 
drug compared with the reference formulation, the hypothesis was that the ratio of the 
mean Tmax, Cmax and AUC0-∞ of the reference and comparison drug lies between 0.8 (4/5) 
and 1.25 (5/4).  
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4.5 Results 
 All horses successfully completed the study and no adverse events were noted. 
Median intra-run variability for omeprazole concentration was 4.8% [IQR: 3.5 – 6.3%].  
Median inter-run variability was 13.2% [IQR: 6.3 – 17.6%]. The median coefficient of 
determination (R2) for the calibration curve was >0.99 [IQR: >0.99 - >0.99].  
 Figures 4.1 shows scatter plots for Tmax, Cmax and AUC0-∞ for each of the 
formulations of omeprazole.  Each of the comparison formulations Tmax, Cmax and AUC0-∞ 
were compared with the reference formulation.  There were no statistically significant 
differences in Tmax, Cmax and AUC0-∞ between the reference formulation and comparison 
formulations for any variables, except between Tmax (P=0.029) and Cmax (P=0.036) of 
GastroGard® and Abgard®. The ratio and back-transformed 90% confidence interval 
between the comparison formulations and reference formulation for Tmax, Cmax and AUC0-∞ 
are shown in Figure 4.2. Bioequivalence between the reference formulation and any of the 
comparison formulations could not be demonstrated. .  Horses that received Omoguard® 
after GastroGard® had a lower Tmax than those that received Omoguard
® before 
GastroGard® (P=0.003).  
4.6 Discussion 
 The results of the present study suggest that there may be modest pharmacokinetic 
differences present between some commercially available formulations of omeprazole in 
the horse.  However, when compared with the reference standard formulation, the 
differences were not statistically significant for three of the formulations evaluated in the 
present study.  The fourth formulation (Abgard®) was an exception with a lower Cmax and 
longer Tmax than the reference formulation (GastroGard
®) observed.  The clinical 
significance of this is unclear as AUC, which did not differ statistically between the two 
formulations, is considered to be the primary determinant of efficacy in humans [102]. 
Further Abgard® has previously been demonstrated to be efficacious in the treatment of 
squamous gastric ulceration in horses at a rate comparable to previous reports for 
GastroGard® [9]. 
The pharmacokinetic profiles of the enteric coated granule formulations (Gastrozol®; 
BOVA Omeprazole Granules) did not differ significantly from that of GastroGard®.  This is 
consistent with a previous study wherein the bioavailability of Gastrozol® was 1.26 times 
higher than GastroGard® but the difference was not statistically significant as a wide 95% 
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confidence interval (95% CI: 0.56 – 2.81) was present [69].  Together, these results 
suggests that minimal, if any difference, exists between the pharmacokinetics of enteric 
coated granule formulations and buffered formulations.  This is in contrast to plain, 
unprotected omeprazole which has been previously reported to have approximately half 
the bioavailability of an enteric coated granule formulation [100]. 
The inability to demonstrate a difference between enteric coated granule 
formulations and buffered formulations is interesting in light of recent clinical studies.  
Gastrozol® at a dose of 1 mg/kg PO once daily has recently been demonstrated to be non-
inferior to the same formulation administered at the reference dose  of 4 mg/kg PO once 
daily in the treatment of naturally occurring gastric ulceration in Thoroughbred racehorses 
[8].  The rates of  endoscopic healing observed in that study were comparable to those 
previously reported for GastroGard® [5–7,50,94,95].  Similarly, no difference in healing of 
endoscopic lesions was observed in a trial comparing Gastrozol® at 1 mg/kg PO once daily 
against GastroGard® at 4 mg/kg PO once daily [69].  Given that a difference in 
pharmacokinetics between enteric coated granule formulations and buffered formulations 
could not be demonstrated in this study, these findings suggest that doses of buffered 
formulations of omeprazole lower than 4 mg/kg PO once daily may be efficacious.  
However, further studies are needed to document this as in a small study investigating the 
efficacy of a low dose of a buffered formulation of omeprazole (Abgard®) at 1.6 mg/kg PO 
once daily was inferior to the reference dose of 4 mg/kg PO once daily of the same 
formulation [10].   
Despite the lack of a significant difference between the formulations being present 
bioequivalence could not be demonstrated.  One potential explanation for this is the small 
sample size in the current study.  Alternatively, true bioequivalence may not be present 
and as such care should be taken in directly extrapolating the results of studies, especially 
clinical studies, between formulations.  Further studies comparing different formulations in 
larger samples of animals are warranted. 
An effect of the order of administration on the Tmax of Omoguard
® was observed, 
wherein horses that received Omoguard® after GastroGard® had a lower Tmax than those 
that received Omoguard® before GastroGard®.   The potential for a type I error increases 
as the number of tests performed increases and the authors consider that it is likely that 
the finding is a statistical aberration as no biological reasons exists why such an effect 
should be present as it has previously been shown that prior administration of omeprazole 
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does not affect the pharmacokinetics of subsequent doses in the horse [3].  However, 
even if present, it is unlikely to be of clinical significance as AUC, not Tmax, is considered 
the primary determinant of efficacy in humans [102]. 
 The results of this study, in agreement with previous work, suggest that the 
pharmacokinetics of omeprazole as enteric coated granules in paste is similar to the 
pharmacokinetics of buffered formulations of omeprazole.  However, bioequivalence could 
not be demonstrated for any of the formulations against the reference formulation and 
further studies with larger numbers of animals are needed to investigate whether the 
formulations studied are truly bioequivalent.   
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Table 4.1 - Trade names and formulation details of the five commercial omeprazole formulations studied. 
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Figure 4.1 - Scatter plots of Tmax, Cmax and Area-Under-the-Curve (AUC0-∞) for the five formulations tested (GastroGard (GG), Abgard, 
(AG), Omoguard (OG), BOVA Omeprazole Granules (BO), Gastrozol (GZ)). * denotes significantly (P>0.05) different from the reference 
formulation (GastroGard). 
 
  
83 
 
Figure 4.2 - The ratio and back-transformed 90% confidence interval between the comparison formulations (Abgard, (AG), Omoguard 
(OG), BOVA Omeprazole Granules (BO), Gastrozol (GZ)) and reference formulation (GastroGard (GG)) for Tmax, Cmax and Area-Under-
the-Curve (AUC0-∞). Dotted lines represent limits of bioequivalence. 
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Figure 4.3 - Mean (+ SD) plasma omeprazole concentration over time for five commercial formulations ((Abgard, (AG), Omoguard (OG), 
BOVA Omeprazole Granules (BO), Gastrozol (GZ)) and reference formulation (GastroGard (GG)). 
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Chapter 5 - Placement of an indwelling percutaneous gastrotomy (PEG) tube for the 
measurement of intra-gastric pH in two horses. 
This chapter consists of a paper published as: 
Sykes BW, McGowan C, Mills P. C. Placement of an indwelling percutaneous 
gastrotomy (PEG) tube for the measurement of intra-gastric pH in two horses. 
Equine Vet. Edu. 27, 627-632 (2015). 
5.1 Prelude  
 As discussed earlier; the methodology used to investigate the pharmacodynamics 
of omeprazole in the earlier studies evaluating the use of omeprazole in the horse may not 
be truly reflective clinical conditions.  Specifically the need to fast horses for the collection 
of gastric fluid may change the subsequent pH measurements obtained.  More recently the 
use of pH probes fitted in a retrograde manner into indwelling gastric cannulas has been 
described [11]. This approach offers several advantages, most notably the ability to 
investigate the pharmacodynamics of omeprazole, and other acid suppressive agents, 
under normal dietary management.  A downside of the later technique is the need for 
general anaesthesia and significant surgical skill to place the indwelling catheters.  Most 
recently the endoscopic assisted placement of indwelling percutaneous gastrotomy (PEG) 
tubes has been described in the horse [103].  This combination of these two techniques is 
appealing as an alternative means of measuring intra-gastric pH in the horse. 
 The objective of the present study was; 
 To describe a method of intra-gastric pH measurement using a pH probe that is 
fitted in a retrograde manner into an endoscopically placed, indwelling PEG in the 
horse.   
5.2 Abstract 
Intra-gastric pH monitoring is an important tool in the validation of acid suppressive 
drugs.  To date, several methods of monitoring intra-gastric pH in the horse have been 
described.  However significant limitations are present in the existing models.  This case 
report describes the placement of a PEG tube secured with a button gastropexy in the 
standing horse through which the pH of the ventral stomach can readily be measured 
under both fed and fasted conditions.  
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5.3 Introduction 
Suppression of gastric acid production is a cornerstone of the treatment of EGUS 
with omeprazole the drug most commonly used for this purpose.  Early studies into the 
efficacy of omeprazole suggested that, using enteric coated omeprazole pellets in gelatine 
capsules, doses as low as  1.4 mg/kg BW given via nasogastric tube result in effective 
acid suppression for a minimum of 27 hours [4].  More recently it has been reported that 
the duration of acid suppression achieved following the oral administration of 4 mg/kg BW 
of a buffered formulation of omeprazole may result in a duration of acid suppression as 
short as 11 hours [11].  Potential reasons for these discrepancies include variation in the 
bioavailability of the different formulations and the reliability of the models used to study 
intra-gastric pH.   
Recent studies have suggested that minimal, if any, differences are present 
between the bioavailability of enteric coated granule formulations and buffered 
formulations of omeprazole in horses.  In a clinical study evaluating the efficacy of two 
formulations of omeprazole in horses, the bioavailability of an enteric coated granule 
formulation was 1.26 times higher than the comparison buffered formulation, although the 
difference was not statistically significant as wide 95% confidence intervals (95% CI: 0.56 
– 2.81) were present [69].  In a study by the authors’ research group the bioavailability of 
two enteric coated granule formulations was tested against a reference buffered 
formulation (GastroGard®).  No significant difference was present between Cmax, Tmax and 
AUC for either formulation [104].  Together, these findings suggest that minimal, if any, 
differences are present between the pharmacokinetics of enteric coated granule and 
buffered formulations of omeprazole in horses.  Direct comparison between the studies of 
Jenkins et al (1992) and Merritt et al (2003) is not possible; however the lack of differences 
in pharmacokinetic between currently available formulations suggests that alternative 
reasons, other than formulation, for the discrepancy in efficacy discussed above warrants 
consideration. 
A limiting factor in any study of gastric acid suppression is a suitable model to 
accurately and reliably measure intra-gastric pH over time.  Early studies used fasted 
horses to allow collection of gastric fluid [4,78], but this may affect the bioavailability of 
buffered omeprazole. One study showed fasted horses had a three-fold increase in 
bioavailability  compared to fed horses [3].  In contrast, Merritt et al (2003) reported a 
model in which pH probes were fitted in a retrograde manner through surgically implanted 
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gastric cannulas.  This method allowed intra-gastric pH to be monitored in horses under 
fed or fasted conditions and without interruption to their normal feeding behaviour and, 
therefore, is more clinically relevant. However, the need for general anaesthesia and 
advanced surgical skills for the placement of the gastric cannula could be considered as 
disadvantages of this model. 
The purpose of this report is to describe a method of intra-gastric pH measurement 
using a pH probe that is fitted in a retrograde manner into an endoscopically placed, 
indwelling PEG in the horse.   
5.4 Animals and animal ethics 
Two healthy, male adult (505 kg and 540 kg; aged 8 and 10 years) Thoroughbred 
horses were used.   Both animals had been in the investigators’ possession for a minimum 
of 12 months prior to use in the study, during which time they had received routine health 
care and remained healthy.  Clinical examination was performed on both horses prior to 
use in the study and was unremarkable.  During the studies the horses were housed 
individually in 16 m2 stables bedded with wood shavings and fed as per the protocol for the 
allocated treatment (see below).  The study was performed under an ethics permit from 
the New South Wales Department of Primary Industries (TRIM 14/981).   
5.5 Materials and Methods 
Horses were fasted for 20 hours and withheld from water for 2 hours prior to 
gastroscopy.  Procaine penicillin (Propercillin®, Troy Laboratories, Glendenning, NSW, 
Australia) (25,000 IU/kg BW intramuscularly) was administered 2 hours prior to 
gastroscopy.  Flunixin meglumine (Flunixon Injection®, Norbrook Laboratories, 
Tullamarine, VIC, Australia) (1.1 mg/kg BW IV) and gentamicin (Gentam 100®, Troy 
Laboratories, Glendenning, Australia) (8.8 mg/kg BW IV) were administered at the time of 
sedation.  The horses were sedated with detomidine (Dozadine®, Virbac, Milperra, NSW, 
Australia) (10-20 µg/kg IV) and gastroscopy was performed using a 3.3. meter 
gastroscope (Portascope®, Portascope.com, Bradenton, FL, USA) as previously described 
[105].  Following introduction of the gastroscope the stomach was insufflated with air until 
fully distended.   
A “button gastropexy” similar to the abomasal toggle technique described in cattle 
[106] was then performed using the following method; the stomach was identified on the 
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left-hand side of the horse at the 11th inter-costal space by percutaneous ultrasound and 
the surrounding area of skin aseptically prepared.  A 2.1 x 133 mm (14 G x 5.25”) catheter 
(Angiocath®, BD, North Ryde, NSW, Australia) was inserted through the skin and into the 
stomach until it could be observed gastroscopically.  Once the location of the catheter was 
visually confirmed within the stomach a 3 m length of high tensile (40 lb.) fishing line was 
passed through the catheter from the outside and into the stomach (figure 5.1).  Biopsy 
forceps were used to grasp the fishing line and draw it into the gastroscope.  The 
gastroscope was then withdrawn, drawing the fishing line out of the nostril.  A generic 15 
mm wide button was then attached to the fishing line and carefully secured.   
The catheter was withdrawn from the body wall and gentle traction was placed on 
the fishing line drawing the button back through the nostril and down the oesophagus and 
into the stomach.  Once firm pressure was felt, suggesting that the button was in place 
against the body wall, the gastroscope was reinserted into the stomach to confirm the 
positioning of the button against the stomach wall (figure 5.2).  A second button was 
placed approximately 3 – 5 cm away from the first button using the same technique.  The 
ends of the two lines were then tied together under gentle traction against the body wall 
with a small plastic plate placed between the suture and the skin to offset the tension 
(figure 5.3).  
Once the gastropexy was placed, a 20 Fr PEG tube (Mila International, Erlanger, 
KY, USA) was then placed using a similar technique.  A similar PEG technique has 
previously been described; without first creating a gastropexy [103]. However, in pilot 
investigations using this technique the authors of this study twice experienced 
displacement of the PEG tube since it was not adequately secured within the stomach. In 
a further modification to the previous described technique, and to further reduce the risk of 
PEG tube displacement, a generic 15 mm nylon washer was placed over the PEG tube 
prior to placement such that it sat between the end of the PEG tube and body wall as 
shown in figure 5.4.    Figure 5.3 shows the gastropexy and PEG tube in place externally. 
A video demonstrating placement of the button gastropexy and PEG tube is available at 
https://dl.dropboxusercontent.com/u/13295715/Movie%20-%20Tube%20Placement.mp4 . 
Following the procedure, horses were returned to their stalls and allowed to recover 
from sedation before being fed as per their normal routine.   Procaine penicillin (25,000 
IU/kg BW IM twice daily), gentamicin (8.8 mg/kg BW IV once daily) and flunixin meglumine 
(1.1 mg/kg BW IV twice daily) were continued for three days at which point in time the 
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horses were changed to doxycycline (Bova Compounding, Caringbah, NSW, Australia) (10 
mg/kg PO twice daily) and phenylbutazone (P-Butazone®, Virbac, Milperra, NSW, 
Australia) (2.2 mg/kg PO once daily) for a further 7 days.  Horses were monitored by full 
clinical examination, including examination of the gastropexy/PEG tube site, three times 
per day for the first two weeks.  Further, examinations, such as ultrasound and/or 
abdominocentesis, were not performed as they were not deemed indicated based on the 
clinical condition of the horses.  On-going monitoring consisted of twice daily monitoring of 
general demeanour, appetite and temperature as well as examination of the 
gastropexy/PEG tube site.  
Three weeks following placement of the PEG tube the position of the tubes was 
confirmed gastroscopically.  In both horses the tube was located within the ventral 
glandular fundus approximately 10 - 15cm below the margo plicatus of the greater 
curvature as shown in figure 3.  At this point a pH probe (Comfortec PLUS®, Sandhill 
Scientific, Highlands Ranch, CO, USA) was fitted retrograde through the PEG tube with its 
location confirmed endoscopically as shown in figure 5.5.  The probes contained two 
measurement points, 5 cm apart.  The location of measurement point 1 was approximately 
1 - 2 cm from the glandular mucosa while the second measurement point (measurement 
point 2) sat 5 cm deeper within the glandular portion of the stomach. The probe’s insertion 
distance into the PEG tube was noted for future placement which was performed blindly 
using the known insertion distance. 
The ability of the model to monitor changes in gastric pH in horses on different feed 
types was then investigated using a cross over study design. The horses were adapted to 
one of two diets over a period of one week; a hay only diet (HAY) or a high grain/low fibre 
(HG/LF) diet.  The HG/LF diet consisted of 1% BW each of grain and hay per day, divided 
equally into two meals fed at 10 am and 6 pm to mimic the management of a racehorse in 
training. The HAY diet consisted of ad libitum access to oaten/rye grass hay.   
Once adapted to their respective diet the intra-gastric pH of each horse was then 
monitored for a period of 5 consecutive days.  To achieve this; the pH probe was attached 
to a continuous data logger (ZepHr®, Sandhill Scientific, Highlands Ranch, CO, USA). 
Data recording commenced at 8 am and continued until 7 am the following morning (23 
hours). Mean, median, minimum and maximum pH and the % time below a pH of 4 was 
reported directly from the software program.  New probes were used for each study period 
and each probe was calibrated each day as per the manufacturer’s instructions.  The 
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probe was then inserted the previously determined distance and secured.  Following the 5 
day data collection period each horse was then transitioned to the other diet over a period 
of one week and the 5 day recording period was repeated on the other diet.  Due to the 
small number of animals and data points collected statistical analysis was not attempted.  
Instead the results for each variable are presented descriptively in table 1 as median 
(IQR).   
5.6 Results 
The procedure was well tolerated by both horses.  Both horses had a mild fever 
(<39.0 oC) within the first 48 hours following the procedure but retained a normal appetite, 
and had otherwise normal clinical parameters.  Forty-eight hours following the 
discontinuation of the antimicrobials on day 10 one horse developed mild, generalised 
swelling of the surgical site and a fever (up to 39.0oC).  Antimicrobial therapy with 
doxycycline (10 mg/kg PO twice daily) was reinitiated for a further 7 days.  The horse 
responded within 24 hours and no further episodes of fever were observed.  At the time of 
writing the tubes have been maintained in place for 6 months without further complication, 
during which time the horses have been used repeatedly for intra-gastric pH measurement 
as part of on-going studies. 
Typical plots of pH over time for the HG/LF and HAY diets are shown in figures 5.6 
and 5.7.  Spikes in the recorded pH were typically seen following the morning feeding at 
10 am in the HG/LF diet with a less consistent effect observed following the 6 pm feeding.  
In the HAY diet the pH typically remained low throughout the measurement period with 
less variation observed. 
Table 5.1 summarises key pH values and the percentage of time below a pH of 4 
for five consecutive days of pH measurement (measured from 8 am to 7 am) for two 
horses under the two different dietary conditions. 
5.7 Discussion 
 This report describes the successful placement of a permanent indwelling PEG tube 
in the standing horse through which intra-gastric pH measurement can readily be 
performed.  Beyond the requirement for a gastroscope, no specialised equipment is 
required and the technique is technically relatively simple with no specialised surgical skill 
required. The procedure was well tolerated by the two horses, both in the short and long 
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term.  Minor complications were observed and further evaluation in a larger number of 
horses is warranted to further document the safety of the procedure.  
The ability to continuously record intra-gastric pH without altering the horse’s 
normal eating behaviour provides a useful model for investigating the efficacy of 
omeprazole and other acid suppressive drugs, which are the cornerstone of the 
management of EGUS, under clinically relevant conditions.  Further, the location of the 
probe within the ventral region of the stomach may provide useful information in 
investigating the poor response of lesions within the glandular mucosa to omeprazole 
monotherapy as recently reported [8–10]. 
The model is similar to a gastric cannulation model previously used in a number of 
studies including those investigating the effect of pasture turnout vs. stall housing on 
gastric pH [40] and the efficacy of omeprazole in suppressing gastric acidity [11].  The 
primary advantage of the current model is the ability to place the PEG tube in the standing 
horse, negating the need for general anaesthesia.  The authors consider that the greatest 
strength of both the previously reported gastric cannulation model and the current PEG 
tube technique is that the location of the probes within the stomach is known.  This is in 
contrast to another model that has been described to measure ventral gastric pH that 
utilises a mercury weighted balloon [71].  This method can be performed in in the standing 
horse but the final location of the pH probe is unknown.  Further, the use of mercury 
presents significant health risks to the operator making this model undesirable. 
The different pH profiles observed between the two diets is interesting and warrants 
discussion.  As shown in figure 6 a spike in pH of approximately 1 – 3 hours duration was 
typically observed following morning, and to a lesser degree evening, feeding in the HG/LF 
group whereas the intra-gastric pH in the HAY group (figure 7) remained relatively stable 
with a pH of < 2.  Reflective of this, the median percent time that the pH was below 4 
appeared lower with the HG/LF diet than the HAY diet.  The number of animals in this 
study is too small to draw conclusions, but further investigation into the effect of diet on 
ventral gastric pH in a larger number of animals appears warranted. 
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Table 5.1 – Summarised values for five 23 hour periods (8 am – 7 am the following day) for pH and the percentage of time below a pH of 
4 recorded over five consecutive days in two horses under two different dietary conditions; ad libitum hay (HAY) and a high grain/low-
fibre diet (HG/LF) consisting of 1% each of grain and hay divided into two meals.  Measurement was performed at two points. 
Measurement point 1 was within 1–2 cm of ventral glandular mucosa. Measurement point 2 was 5 cm distal to measurement point 1. 
Data shown as median (IQR). 
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Figure 5.1 - A gastroscopic image taken following transcutaneous insertion of a 14 G x 
5.25” catheter into the stomach. A length of high tensile (40 lb.) fishing line is then passed 
through the lumen of the catheter and into the stomach. 
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Figure 5.2 - A gastroscopic image showing the positioning of the button within the ventral 
glandular mucosa below the greater curvature (left of image) and looking towards the 
lesser curvature and pyloric antrum. 
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Figure 5.3 - An image showing placement of the percutaneous gastrotomy (PEG) tube 
(top) and button gastropexy (bottom) at between 11th and 12th ribs. 
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Figure 5.4 - A gastroscopic image showing final placement of the button gastropexy and 
percutaneous gastrotomy (PEG) tube. Prior to PEG tube insertion a 25 mm nylon washer 
is placed over the shaft of the PEG tube to provide additional security against the stomach 
wall. 
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Figure 5.5 - A gastroscopic image showing final placement of the pH probe with two 
measurement points 5 cm apart. The first measurement point is located approximately 1–2 
cm from the surface of the mucosa. The second measurement point sits freely within the 
ingesta/fluid contents of the ventral stomach. 
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Figure 5.6 - An example of a trace of continuous pH measurement of the ventral stomach over a 23 hour period in a horse (horse 1 – day 
1) 6 receiving a high grain/low fibre (HG/LF) diet consisting of 1% each of grain and hay divided equally into two meals fed at 10:00 am 
and 6:00 pm. The top trace is from measurement point 1 and the lower trace is from measurement point 2. 
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Figure 5.7 - An example of a trace of continuous pH measurement of the ventral stomach over a 23 hour period in a horse (horse 1 – day 
3) receiving a diet consisting of ad libitum hay. The top trace is from measurement point 1 and the lower trace is from measurement point 
2. 
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Chapter 6 – The effect of dose and diet on the pharmacodynamics of omeprazole in 
the horse. 
This chapter consists of a paper submitted to the Equine Veterinary Journal as: 
Sykes BW, Underwood C, Greer R, McGowan C, Mills P. C. The effect of dose and 
diet on the pharmacodynamics of omeprazole in the horse. 
6.1 Prelude 
 The findings of the earlier studies in this thesis were primarily focused on the 
influence of diet and formulation on the pharmacokinetics of omeprazole in the horse.  The 
findings of chapter 4 suggested that the impact of formulation was minimal.  However, 
bioequivalence between commercially available formulations could not be determined.  As 
such the authors considered it appropriate to select GastroGard® as the formulation for 
evaluation in the final study since it has historically been the most widely used formulation 
globally.   
Although diet could not be shown to be significantly influenced in the studies 
reported in chapter 2 or 3, the authors felt that the raw data and previously published 
literature suggested that an effect may be present.  As such further investigation was 
warranted and two diets, representing difference ends of the clinical spectrum, were 
included for evaluation.  Lastly, the effect of dose has been poorly described with no 
reports of direct comparisons between doses published.   
 Considering this the objective of the study was to use the model for intra-gastric pH 
measurement reported in chapter 5 to; 
 Investigate the effect of two diets, representing different ends of the clinical 
spectrum on the pharmacodynamics of GastroGard® in the horse; and 
 Investigate the effect of two doses on the pharmacodynamics of GastroGard® in 
the horse. 
6.2 Abstract 
Conflicting data is presented in the current literature regarding the efficacy of 
omeprazole for supressing gastric acidity in the horse. The objective of this study was to 
investigate the duration of intra-day acid suppression achieved with two doses of 
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omeprazole under two different dietary conditions using a 4-way cross-over design. Six 
adult, Thoroughbred horses instrumented with percutaneous gastrotomy tubes were used.  
Intra-gastric pH was measured for continuous 23 hour periods (8am – 7am) for 6 
consecutive days (days 0-5).  Baseline data was recorded on day 0 and omeprazole was 
administered on days 1-5.  Two doses (1 mg/kg and 4 mg/kg PO once daily) and two diets 
(a high grain/low fibre (HG/LF) and ad libitum hay (HAY) diet) were studied. Data for the 
percent time pH was above 4 (%tpH>4) and median intra-day pH was reported for two 
measurement points and analysed using generalized estimating equations.  An effect of 
both diet and dose was evident with mean %tpH>4 and mean median intra-day pH 
typically higher at the higher (4 mg/kg) dose and in HG/LF diet. The overall efficacy of 
omeprazole in raising intra-gastric pH was good under the HG/LF conditions but relatively 
poor in the HAY diet.  A cumulative effect of dosing, not previously reported in the horse, 
was observed.  The overall efficacy of omeprazole in raising ventral gastric pH was less 
than previously reported.  Further, the present study suggests that both dose and diet may 
play a role in the efficacy of omeprazole in the horse.  As such the use of singular dosing 
recommendations that encompass all horse types and management conditions may not be 
appropriate.  Instead, dosing recommendations that take into account the diet of the horse 
may be advantageous. 
6.3 Introduction  
Equine Gastric Ulcer Syndrome (EGUS) is a common disease of horses worldwide.  
Recently the terminology has been refined to recognise Equine Squamous Gastric 
Disease (ESGD) and Equine Glandular Gastric Disease (EGGD) as separate entities [1]. 
Regardless of the lesion type omeprazole is recommended as the treatment of choice [1] 
and it is widely used for this purpose.  Early studies investigating the pharmacodynamics 
of omeprazole in the horse suggested that it has a 24 hour duration of activity following 
enteral administration [3,4].  Its efficacy in the treatment of ESGD in a number of clinical 
studies [5–7] appeared to support this conclusion. 
The results of these early studies were recently questioned by a study that 
measured intra-gastric pH of horses on an ad libitum hay diet using pH probes inserted 
retrograde into an indwelling gastric cannula [11].  In this study [7], the commercially-
available formulation GastroGard® was compared to three compounded formulations of 
omeprazole with intra-gastric pH of the ventral stomach continuously recorded for 24 hour 
periods in horses fed ad libitum hay supplemented with a small grain meal twice daily.  
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Although GastroGard® was the most efficacious of the treatments studied, the time mean 
pH was above 4 was only 14 and 11 hours on days 2 and 7 of treatment, respectively.  
This is in contrast to the findings of earlier studies [2,3], but whether this was an effect of 
feeding or the formulation studied was not established. 
The possibility that the duration of acid suppression achieved under clinical 
conditions may be less than originally reported in experiment studies is further supported 
by recent studies where the EGGD treatment response was only 25% with 28-35 days of 
omeprazole therapy at 4.0 mg/kg PO once daily in direct contrast to ESGD lesion healing 
rate of 78% in the same studies [8–10].  One of the possible explanations for this lower 
response rate is that the duration of intra-day acid suppression required for healing of 
ESGD may less than that required for healing of EGGD. As such, ≤ 14 hours of acid 
suppression may be adequate for ESGD healing, while EGGD healing may require acid 
suppression of a longer duration.   
The objective of this study was to further investigate the duration of intra-day acid 
suppression achieved with two doses of omeprazole under two different dietary conditions 
using a recently described gastric cannulation model [107] that allows continuous 
monitoring of gastric pH under normal feeding conditions. 
6.4 Materials and Methods 
6.4.1 Horses  
Six (3 male, 3 female) healthy Thoroughbred horses (aged 7 to 14 years, 480 – 565 
kg BW) were used. Horses were housed in 16 m2 stables and bedded on wood shavings 
throughout the study.  Horses were feed a rye grass/lucerne hay mix ad libitum that was 
supplemented with a commercial feed pellet as required to maintain body condition 
throughout the study period unless otherwise dictated by the diet under investigation.  
Each horse was instrumented with a percutaneous gastrotomy tube (PEG) as previously 
described [107].  The location of the PEG tube was confirmed by gastroscopy to be within 
the ventral glandular fundus approximately 10 – 15 cm below the margo plicatus adjacent 
to the lesser curvature in each horse.   
6.4.2 Group allocation 
Horses were assigned to treatment pairs with one pair studied each week in a 4-
way cross over design.  Two diets were evaluated; a hay only diet (HAY) or a high 
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grain/low fibre (HG/LF) diet.  The HG/LF diet consisted of 5 kg grain (40% protein pellets 
(Equine Mare and Foal™, Vella Stock Feeds, Plumpton, NSW, Australia) and 60% sweet 
feed (Robank Non-Oat Custom Mix™, Robank, Ebenezer, NSW, Australia)) and 5 kg hay 
per day, divided equally into two meals fed at 10 am and 6 pm to represent typical dietary 
management of a racehorse in training [80]. The HAY diet consisted of ad libitum access 
to a rye grass/lucerne hay mix.  Horses were adapted to the diets over a period of at least 
1 week prior to the commencement of data collection.  Water was available ad libitum. The 
remaining 4 horses rested and, where appropriate, transitioned between test diets.   
6.4.3 Administration of medication 
 Two doses of omeprazole (GastroGard®) were evaluated; 1 mg/kg PO once daily 
and 4 mg/kg PO once daily.  To ensure accurate dosing each horse was weighed on 
electronic scales (Accuweigh Equestrian Scales®) on day -1.  The omeprazole was 
administered using the graduated dose markings on the syringe, rounding up to the 
nearest 50 pound (22.7 kg) dose.  Medications were administered at 8 am (2 hours prior to 
feeding in the HG/LF diet). 
6.4.4 Gastric pH measurement 
 Once adapted to their respective diet the intra-gastric pH of each horse was then 
monitored for a period of 6 consecutive days.  To achieve this; the pH probe was attached 
to a continuous data logger (ZepHr pH®) and calibrated prior to placement each day as per 
the manufacturer’s instructions.  The probe was then inserted a previously determined 
distance and secured as previously described [107].  Data was recorded at 2 points; 
measurement point 1 was located approximately 10 – 20 mm from the glandular mucosa 
and measurement point 2 was 5 cm further within the stomach as shown in figure 6.1 
[107].  Data recording commenced at 8 am and continued until 7 am (23 hours). Mean 
intra-day, median intra-day, minimum and maximum pH and the % time below a pH of 4 
was reported directly from the data logger’s software program.    The % time above a pH 
of 4 (%t>pH4) was calculated using the following equation: % time above a pH = 100% - % 
time below a pH of 4. Baseline data was recorded on day 0 with the medication 
administered on days 1 – 5.   
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6.4.5 Data analysis 
Data were assessed for normality. Distributions and correlations were screened 
graphically and using Pearson's or Spearman's correlation coefficient, with coefficients  
<0.4 regarded as poor, 0.4–0.7 moderate and >0.7 good [108].  Summary statistics are 
reported as estimated marginal means.  Differences between groups over time were 
assessed using generalized estimating equations (GEE) utilizing the 'genlin' command in 
SPSS (www.ibm.com/software/au/analytics/spss) with ARIMA (Autoregressive Integrated 
Moving Average) selected as the optimal covariance structure. A GEE is conceptually 
similar to repeated measures ANOVA, in that it accounts for repeated measures on 
individual horses. GEE can be used when there are missing data points, and provides a 
more realistic covariance structure than ANOVA which assumes compound symmetry. In 
compound symmetry, the assumption is that the correlation between data points within 
individual animals is constant. ARIMA better models the situation where the correlation 
decreases with increasing 'distance' between the points, for example measurements taken 
at time point 1 and time point 2 are more similar than measurements taken at time point 1 
and time point 5.  
For each measurement point, separate GEE models were used to evaluate the 
effect of the explanatory variables dose and time, and feed and time, on the two outcome 
measures, median intra-day pH and %t>pH4. Models assessing the effect of drug dose 
were run for each type of feed and measurement point, and conversely models assessing 
the effect of feed were run for each dose of drug and measurement point. Median intra-day 
pH and %tpH>4 for day 1 to day 5 were included for each model. Baseline (day 0) median 
intra-day pH or %tpH>4 was included as a covariate in each model. Within each model 
day 1 was compared day 5. A Bonferroni correction was applied to these comparisons 
resulting in a P value of <0.0016 being considered significant. For all other comparisons 
significance was set at P<0.05. Graphs were created using GraphPad Prism 
(www.graphpad.com/scientific-software/prism). 
6.4.6 Animal ethics 
The study was performed under an ethics permit from the New South Wales 
Department of Primary Industries (TRIM 14/2710 (7)). 
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6.5 Results 
The majority of the data were normally distributed. From the 578 data points there 
were 22 (3.8%) missing values. Figures 6.2 and 6.3 show the effect of dose and diet on 
mean %t>pH4 and mean median intra-day pH, respectively. 
6.5.1 Effect of diet and location 
There was no difference between mean %t>pH4, over days 1 to 5 combined, at 
measurement point 1 on the HG/LF compared to the HAY diet on either dose. However, at 
measurement point 2 the mean %t>pH4, over days 1 to 5 combined, was higher on the 
HG/LF diet than the HAY diet when the horses were on a 4 mg/kg dose at (69% vs. 22% 
respectively, p<0.001) and at the 1 mg/kg dose (49% vs. 16% respectively, p<0.001). 
There was no difference in mean median intra-day pH, over days 1 to 5 combined, 
on the HG/LF diet compared to the HAY diet when the horses were on a 4 mg/kg dose at 
measurement point 1. However, mean median intra-day pH, over days 1 to 5 combined, 
was higher on the HG/LF diet compared to the HAY diet when on a 4 mg/kg dose at 
measurement point 2 (4.9 vs. 2.9 respectively, p<0.001). There was no difference between 
mean median intra-day pH, over days 1 to 5 combined, on the HG/LF compared to the 
HAY diet when the horses were on a 1 mg/kg dose at either measurement point 1 or 2.  
6.5.2 Effect of Dose and location 
The mean %t>pH4, over days 1 to 5 combined, was higher on the 4 mg/kg dose 
compared to the 1 mg/kg dose at both measurement points when horses were on the 
HG/LF diet (88% vs. 57% respectively at measurement point 1, and 66% vs. 28% 
respectively at measurement point 2, p<0.001). The mean %t>pH4, over days 1 to 5 
combined, at point 2 was also higher on the 4 mg/kg dose vs. the 1 mg/kg dose on the 
HAY diet (19% vs. 4% respectively, p=0.03). There was no difference in mean %t>pH4, 
over days 1 to 5 combined, on the 4 mg/kg dose compared to the 1 mg/kg dose at 
measurement point 1 on the HAY diet 
There were no differences in mean median intra-day pH, over days 1 to 5 
combined, on the 4 mg/kg dose compared to the 1 mg/kg dose on the HAY diet at either 
location (measurement point 1 or point 2). The mean median intra-day pH, over days 1 to 
5 combined, was higher on the 4 mg/kg dose compared to the 1 mg/kg dose when horses 
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were on the HG/LF diet at measurement point 1 (6.4 vs. 4.3 respectively, p<0.001) and 
also at measurement point 2 (4.8 vs. 2.5 respectively, p<0.001). 
6.5.3 Effect of time 
The mean %t>pH4 was higher on day 5 compared to day 1 at measurement point 2 
on both doses on the HG/LF diet (38% vs. 12% respectively on 1 mg/kg and 75% vs. 49% 
respectively on 4 mg/kg, p=0.001).  When comparing day 5 of treatment to day 1 of 
treatment, mean median intra-day pH was higher on day 5 at measurement point 2 on 
both doses and in both diets (1.9 on day 1 vs. 3.3 on day 5 on the HAY diet at a 4 mg/kg 
dose, 3.8 on day 1 vs. 5.3 on day 5 on the HG/LF diet at a 4 mg/kg dose and 1.4 on day 1 
vs. 3.0 on day 5 at a 1mg/kg dose on the HG/LF diet and 3.6  vs. 5.2 on the HG/LF diet at 
a 4 mg/kg dose on the HG/LF diet, p<0.001).  
There was a positive correlation between %t>pH4 at measurement point 1 and at 
measurement point 2 (rs=0.86, p=0.01), but no correlation between median intra-day pH at 
the two points (rs=0.06, p=0.77), as shown in figure 6.4. 
6.6 Discussion 
The results of the present study were surprising as the overall efficacy of 
omeprazole in raising ventral gastric pH was less than previously reported.  Further, the 
present study suggested that both dose and diet may play a role in the efficacy of 
omeprazole in the horse.  As such, the use of singular dosing recommendations that 
encompass all horse types and usages, with their associated differences in management, 
as traditionally recommended [1,17], may not be appropriate.  Alternatively, tailored dosing 
regimens that take into account diet may allow more effective usage of omeprazole in 
clinical practice with lower doses appropriate under conditions similar to the HG/LF diet in 
the present study and higher doses required for horses on ad libitum roughage-based 
diets. 
The results of the current study showed a lower than expected overall efficacy of 
omeprazole.  As such the authors consider it appropriate to review the previous studies on 
which this expectation was based. An early study investigating the pharmacodynamics of 
omeprazole in the horse reported the administration of 1.4 mg/kg of enteric-coated pellets 
in gelatine capsules via nasogastric tube for 6 days [4].  Using a model that involved 
collection of gastric fluid from an indwelling gastric cannula, gastric acid output and acidity 
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were determined. On day 7 basal gastric acidity and acid output were determined between 
24-25 hours post-omeprazole administration and pentagastrin stimulated acidity and acid 
output determined between 26-27 hours. On day 7 at 24-25 hours post dose, basal acid 
output (mmol H+/15 min) was decreased by 90%, while gastric acidity (mmol H+/L) was 
decreased by 66%.  Pentagastrin stimulated gastric acid output at 26-27 hours was 
reduced by 72% and mean pH (3.2 ± 1.5) was significantly higher than control values (1.7 
± 0.7) [4].     
Another study reported the efficacy of an omeprazole paste at 4 mg/kg and 5 mg/kg 
PO once daily [3].   Basal and pentagastrin stimulated gastric acid output and pH was 
evaluated 21-24 hours after 15 doses in thirteen horses.  The results of the study suggest 
that at 4 mg/kg PO once daily profound acid suppression was achieved with basal and 
pentagastrin stimulated gastric acid output reduced by 83% and 90%, respectively, on day 
15 (hours 21-24) [3].  Similarly, on day 15 gastric pH was 5.5 ± 0.47 and 4.32 ± 0.62 (basal 
and pentagastrin stimulated, respectively) at 21-24 hours post-omeprazole administration. 
No differences were present between the 4.0 mg/kg and 5.0 mg/kg dose [3].  
In contrast, a more recent study by Merritt et al measured intra-gastric pH over 24 
hour periods using pH probes inserted retrograde into the indwelling gastric cannula in six 
horses fed ad libitum hay supplemented with a small grain meal twice daily [11].  
GastroGard®, which was compared to three compounded formulations of omeprazole, only 
achieved a pH exceeding 4 for only 14 and 11 hours on days 2 and 7 of treatment, 
respectively.  This is equivalent to a %t>4 of 58% and 46%, respectively.  The time pH 
exceeds 4 was used as the determinant of efficacy as this is widely accepted in human 
medicine as the primary determinant of symptomatic control and healing for the treatment 
of gastroesophageal reflux disease (GERD), a condition the has many similarities with 
squamous ulceration in the horse [11].     
The results of the present study are more consistent with the Merritt et al [11] study 
and probably reflect the methodology used to measure gastric acidity.  The earlier studies 
fasted the horses for 18 – 24 hours prior to the collection of gastric fluid [3,4].  This 
intervention is potentially relevant as fasting increases the bioavailability, as determined by 
area-under-the-curve (AUC), of buffered paste omeprazole formulations by approximately 
200-300% when compared with values from fed horses [3,109]. The primary determinant 
of efficacy of omeprazole in humans [102] and dogs [110] is AUC, and, as such, conditions 
that increase AUC may increase the efficacy of omeprazole.  Conversely, conditions, such 
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as the ad libitum diet used in the present study and that reported by Merritt et al [11] may 
decrease the bioavailability, and thus efficacy of omeprazole.  However, it should be noted 
that direct comparison between the findings of the present study and that of Merritt et al is 
difficult as the experimental methodology had subtle, but potentially significant differences.  
These include the location of the gastric cannula which was truly ventral in the Merritt et al 
study [11] and located below the lesser curvature in the present study, and the depth of 
insertion of the probes, reported as “5 cm into the gastric lumen” in the Merritt et al study 
[11] and approximately 10-20 mm and 60-70 mm for measurement point 1 and 2, 
respectively, in the present study.  
Further uncertainty was apparent in the earlier studies since it is not known whether 
fasting itself will affect gastric acid production from the parietal cell, or if the pentagastrin 
stimulation model used in these studies induced gastric acid output equivalent to feeding. 
It is therefore possible that the experimental design of these earlier studies fluid may have 
inadvertently and incorrectly concluded a higher efficacy of omeprazole than that which is 
achieved when it is administered to fed horses.   
An important outcome from the current study was that omeprazole at 4 mg/kg PO 
once daily in the high grain/low fibre diet was highly efficacious in the suppression of 
gastric acidity with a predicted %t>pH4 exceeding 80% from day 1 onwards.  These 
findings are consistent with clinical studies in Thoroughbred racehorses on the same diet 
where resolution of ESGD, as evaluated by endoscopy, is reported to be 70-80% with 28 
days of omeprazole therapy at 4 mg/kg PO once daily [5–7,10,50]. Interestingly, a recent 
study has reported non-inferiority of 1 mg/kg, compared with 4 mg/kg, PO once daily in the 
treatment of clinical ESGD in a Thoroughbred racehorse population fed a similar diet [80], 
which  suggested that lower doses may be equally efficacious clinically under specific 
conditions [8].  Although the non-inferiority study used an enteric-coated formulation of 
omeprazole that differed from the buffered formulation evaluated in the current study, two 
recent studies have found no-significant difference in bioavailability, as measured by AUC, 
between the two formulations [69,104]. As such it is unlikely that the efficacy of the low 
dose was attributable to the formulation used.  Instead, it suggests that the %tpH>4 
achieved at 1 mg/kg PO once daily is adequate for ESGD healing to occur, at least under 
the conditions studied.     
 In contrast to the magnitude of acid suppression observed in the HG/LF, relatively 
poor acid suppression was observed in the HAY diet (predicted day 5 %tpH>4 was 
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approximately 40% and 30% for measurement points 1 and 2, respectively, on 4 mg/kg 
PO once daily, and 30% and <10% for measurement points 1 and 2, respectively, on 1 
mg/kg PO once daily).  Similarly, relatively low levels of suppression where observed at 
measurement point 2, when compared with measurement point 1.  Although the exact 
location of the tip of the probe, and thus measurement point 2, was not known it can 
reasonably be expected that it is likely to be buried in the ingesta.  Accordingly it is likely 
that the ingesta had an effect on the regional pH, and would likely have muted the 
magnitude of changes in measured pH as well as potentially affecting the dynamics of 
such changes.   
The authors propose that the low magnitude of suppression observed with the HAY 
diet suggest that dose reduction of omeprazole below 4 mg/kg PO once daily is not 
advisable for the treatment of EGUS in patients on an ad libitum hay/roughage based diet.  
Further, the results of the present study suggest that current dosing regimens may not be 
appropriate for use in horses on ad libitum hay/roughage based diets. Instead the use of 
higher doses, twice daily dosing or alternative PPI’s, which may results in higher 
magnitudes of acid suppression appears to warrant investigation. This may be particularly 
relevant for the treatment of EGGD as the outcome reported with omeprazole 
monotherapy in recent clinical studies using current dosing regimens is poor [8–10]. 
The cumulative effect of treatment wherein the magnitude of acid suppression 
observed on day 5 was greater than that for day 1 has not, to the authors’ knowledge, 
been previously reported for the horse.  In interpreting the cumulative effect, it should be 
noted that the effect was not consistently observed under all conditions and that a 
statistically significant effect could only be demonstrated at measurement point 2 under 
specific conditions.  In contrast, visual examination of the data suggests that such an effect 
is not be present at measurement point 1, which likely more accurately reflects conditions 
at the level of the mucosa.  As such the clinical significance of the cumulative effect 
demonstrated is questionable.   
It has been previously suggested that such a cumulative effect is not present in the 
horse [11]. In humans, the efficacy of proton pump inhibitors (PPI’s) is cumulative as their 
short half-life (90 minutes in humans) means that not all pumps will be active during the 
short period when PPI’s are present in the blood [66], so not all pumps will be inactivated 
each day.  This effect is likely to be more pronounced in the horse given its even shorter 
half-life of approximately 30 minutes [74,100].  Alternatively it has been suggested in man 
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that repeated administration of omeprazole may result in impaired clearance due to 
inhibition of the cytochrome p-450 elimination pathway by either omeprazole or a sulphone 
metabolite [79].  A third potential cause that has been proposed is that a self-protective 
effect, wherein subsequent doses of omeprazole are protected by the increase in intra-
gastric pH that occurs following administration of previous doses, may be present [79].      
Another interesting finding of the present study was the differences observed 
between the two measurement points of gastric pH.  For example, there were data points 
where the median intra-day pH at measurement point 1 exceeded 7 while median intra-
day pH at measurement point 2 was <2 (Figure 6.4).  Similarly, although the correlation 
between the probes for %t>pH4 was classified as good, examination of the raw data 
suggests that a wide range of correlations are present.  For example, some values for 
%t>pH4 at measurement point 1 of 100% corresponded with values of 0% at 
measurement point 2.  This finding was surprising, given that the measurement points 
were located only 5 cm apart from each other.  A similar effect has been reported in 
humans, both pre and post-prandial, when intra-gastric pH is measured in multiple 
locations [111].  Regional pocketing of acidity has been described in humans [112] and 
appears to warrant further investigation in the horse, especially when monitoring response 
to treatment with acid suppressive agents as this was when the differences between the 
two measurement points were most obvious (data not shown).  The %t>pH4 and median 
intra-day pH for measurement point 1 were consistently higher than measurement point 2, 
although the clinical significance of this is not known.  It has been suggested in human 
medicine that a single pH electrode does not adequately detect regional differences in the 
stomach and the measurement at multiple probe locations may improve diagnostic 
accuracy [111].  Based on these recommendations and the findings of the present study, 
the authors propose that future studies measuring intra-gastric acidity in the horse should 
measure intra-gastric pH at multiple locations to improve diagnostic accuracy and allow 
more thorough evaluation of potential therapeutic agents, and in particular acid 
suppressive therapy. 
  One potential weakness of the current study was that the horses in the HG/LF diet 
were not specifically fasted.  However, it has recently been reported that many stabled 
horses finish an evening meal before midnight [113] and this was observed by the authors 
of the present study wherein the entire meal in the HG/LF group was consistently 
consumed within 4 hours.  This effectively resulted in a fast of approximately 10 hours 
prior to the morning administration of the medication.  Further, the authors believe that the 
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study protocol reflects the real world usage of the medications and thus the findings are 
more applicable to the clinical setting.  Another potential weakness is that the presence of 
the PEG tube and gastropexy may have altered gastric motility.  Analysis of 
pharmacokinetic data collected simultaneously (see chapter 7) on days 1 and 5 reveals 
similar time to maximal concentration values as previously reported in fed horses, 
suggesting that this effect may be less likely, although it cannot be completely discounted.  
Further, a similar model has previously been reported and considered reliable for the 
measurement of intra-gastric acidity in the horse [11].   
6.7 Conclusions 
 The findings of the present study suggest that both dose and diet affect the 
response to omeprazole in the horse.  Relatively high levels of acid suppression were 
consistently observed in the HG/LF diet.  Together with the previously reported efficacy of 
low dose (1 mg/kg PO once daily) omeprazole in clinical patients the findings suggest that 
lower doses of omeprazole may be suitable under conditions which replicate the feeding of 
the HG/LF diet in the present study.  In contrast, the response in the ad libitum hay based 
diet was consistently poor.  These findings suggest that dose reduction is not appropriate 
in a population receiving a roughage based diet.  Instead higher dose, twice daily or 
alternative PPI therapies appear to warrant further investigation. 
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Figure 6.1 - A gastroscopic image showing final placement of the pH probe with two measurement points 5 cm apart. The first 
measurement point is located approximately 10–20 mm from the surface of the mucosa. The second measurement point sits freely within 
the ingesta/fluid contents of the ventral stomach. 
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Figure 6.2 – The effect of dose (1 mg/kg PO once daily and 4 mg/kg PO once daily) on mean %tpH>4 at two measurement points in six 
horses on either a high grain/low fibre diet or an ad libitum hay only diet. 
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Figure 6.3 - The effect of dose (1 mg/kg PO once daily and 4 mg/kg PO once daily) on mean median intra-day pH at two measurement 
points in six horses on either a high grain/low fibre diet or an ad libitum hay only diet. 
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Figure 6.4 – Scatter plots demonstrating the relationship between daily measurements at two different points (measurement point 1 and 
measurement point 2) 5 cm apart in the ventral stomach of 6 horses. 
 
rs=0.86, (p=0.01) 
 
rs=0.06, (p=0.77) 
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Chapter 7 – The effect of dose and diet on the pharmacokinetics of omeprazole in 
the horse. 
This chapter consists of a paper submitted to the Journal Veterinary Pharmacology and 
Therapeutics as: 
Sykes BW, Underwood C, McGowan C, Mills P. C. The effect of dose and diet on 
the pharmacokinetics of omeprazole in the horse. 
7.1 Prelude 
As discussed in the prelude to chapter 6 the findings of the earlier studies in this 
thesis were primarily focused on the influence of diet and formulation on the 
pharmacokinetics of omeprazole in the horse.  The findings of chapter 4 suggested that 
the impact of formulation was minimal.  However, bioequivalence between commercially 
available formulations could not be determined.  As such the authors considered it 
appropriate to select GastroGard® as the formulation for evaluation in the final study since 
it has historically been the most widely used formulation globally.   
Although diet could not be shown to be a significant influence in the studies 
reported in chapter 2 or 3, the authors felt that the raw data and previously published 
literature suggested that an effect may be present.  As such further investigation was 
warranted and two diets, representing difference ends of the clinical spectrum, were 
included for evaluation.  Lastly, the effect of dose has been poorly described with no 
reports of direct comparisons between doses published.   
 Considering this the objective of the study was to further investigate; 
 The effect of two diets, representing different ends of the clinical spectrum on the 
pharmacokinetics of GastroGard® in the horse; and 
 The effect of two doses on the pharmacokinetics of GastroGard® in the horse. 
7.2 Abstract 
 This study aimed to investigate the effect of diet and dose on the pharmacokinetics 
of omeprazole in the horse.  Six horses received two doses (1 mg/kg and 4 mg/kg) of 
omeprazole orally once daily for 5 days.  Each dose was evaluated during feeding either a 
high grain/low fiber (HG/LF) diet and an ad libitum hay (HAY) diet in a four-way cross over 
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design.  Plasma samples were collected for pharmacokinetic analysis on days 1 and 5. 
Plasma omeprazole concentrations were determined by ultra-high pressure liquid 
chromatography-mass spectrometry (UHPLC-MS).    
In horses being fed the HG/LF diet, on day one the Area-Under-the-Curve (AUC) 
and maximal plasma concentration (Cmax) were higher on the 4 mg/kg dose than on the 1 
mg/kg dose.  The AUC was higher on day five compared to day one with the 4 mg/kg dose 
on the HG/LF diet. On days one and five the AUC and Cmax were higher in horses being 
fed the HG/LF diet and receiving the 4 mg/kg dose than in horses being fed the HAY diet 
and receiving the 1 mg/kg dose.  These findings suggest that both dose and diet may 
affect pharmacokinetic variables of omeprazole in the horse.     
     
7.3 Introduction 
 Omeprazole is widely used in the horse for the treatment of equine gastric ulcer 
syndrome (EGUS).  Yet to date the factors that affect the pharmacokinetics of omeprazole 
in the horse have been relatively poorly described.  In humans the effect of cumulative 
dosing, which results in an increased bioavailability over time, is well documented [79], yet 
conflicting evidence exists whether such an effect is present in the horse.   Studies on 
enteric coated granules demonstrated a cumulative effect to be present in one study with 
bioavailability increasing from 6% on day 1 to 13% on day 5 [4], although a different study 
reported a bioavailability of 12% and 14% on days 1 and 5, respectively [78].  Likewise, no 
cumulative effect of dosing was found between days 1 and 14 in a study evaluating the 
pharmacokinetics of a buffered formulation of omeprazole [3].  
Further, the effects of feeding regimen and diet on omeprazole bioavailability in the 
horse are yet to be fully elucidated.  A single study reporting the pharmacokinetics of a 
buffered formulation of omeprazole suggested a potentially significant impact of feeding 
wherein the area-under-the-curve (AUC) in fasted animals was approximately 300% 
greater than in fed animals [3].  In contrast, more recent studies found no significant effect 
of feeding on the bioavailability of an enteric-coated [100,109] or a buffered [109] 
formulation, although a trend of increased bioavailability with feeding was noted, 
particularly for the buffered formulation.   It was therefore apparent that further studies into 
the impact of feeding on bioavailability were warranted.   
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One concern when comparing the pharmacokinetics of omeprazole in the horse in 
early studies was the relatively poor sensitivity of the analytical methods used, as 
evidenced by the failure to detect serum levels of omeprazole in some animals despite 
apparent acid suppression [4,78].  One study evaluating the administration of enteric-
coated pellets in gelatine capsules at 0.7 mg/kg PO once daily found that the AUC could 
only be determined for 5/8 animals [78].  A second, similar study evaluating 1.4 mg/kg of 
enteric-coated pellets in gelatine capsules reported similar results with bioavailability of 
omeprazole only calculable for 5/8 horses studied [4].  Poor sensitivity of analytical 
methodologies, combined with a low and variable bioavailability, could reduce the validity 
of early studies to determine factors affecting the pharmacokinetics of omeprazole in the 
horse. 
The objective of the present study was to further investigate the factors that affect 
the pharmacokinetics of omeprazole in the horse.  Specifically; the effect of diet, dose and 
repeated administration over a 5 day period. 
7.4 Material and Methods 
 GastroGard® (Merial, Duluth, GA, USA) was chosen as the study formulation as it 
has been the predominant formulation available globally for the past 15 years.  It has been 
extensively evaluated in clinical studies that have documented its efficacy in the treatment 
of squamous gastric ulceration at a dose of 4 mg/kg PO once daily [5–7,50,94,95]. It has 
also been evaluated at a prophylactic for squamous ulceration with its efficacy at a dose of 
1 mg/kg PO once daily documented [114–116]. 
7.4.1 Animals and animal ethics 
 Six healthy, adult Thoroughbred horses (aged 5-14 years, 480-565 kg bodyweight 
(BW)) consisting of three male castrates and three females were used. Each horse was 
instrumented with a percutaneous gastrotomy tube (PEG), as previously described [107], 
allowing for the concurrent measurement of intra-gastric pH as part of separate studies.  
Horses were housed in 16 m2 stables and bedded on wood shavings throughout the study.  
Horses were feed ad libitum rye grass-lucerne hay mix that was supplemented with a 
commercial feed pellet (Equine Mare and Foal®, Vella Stock Feeds, Plumpton, NSW, 
Australia) as required to maintain body condition throughout the study period unless 
otherwise dictated by the diet under investigation.  Water was available ad libitum at all 
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times.  The study was performed under an ethics permit from the New South Wales 
Department of Primary Industries (TRIM 14/2710 (7)). 
7.4.2 Group allocation 
Horses were assigned to treatment pairs with one pair studied each week in a four-
way cross over design.  Two diets were evaluated; a hay only diet (HAY) or a high 
grain/low fibre (HG/LF) diet.  The HG/LF diet consisted of 5 kg (1% BW per day for a 500 
kg horse) grain (40% protein pellets (Equine Mare and Foal®, Vella Stock Feeds, 
Plumpton, NSW, Australia) and 60% sweet feed (Robank Non-Oat Custom Mix®, Robank, 
Ebenezer, NSW, Australia)) and 5 kg (1% BW per day for a 500 kg horse) hay, divided 
equally into two meals fed at 10 am and 6 pm to represent typical dietary management of 
a racehorse in training [80]. The HAY diet consisted of ad libitum access to rye grass-
lucerne hay.  Horses were adapted to the diets over a period of at least 1 week prior to the 
commencement of data collection.  The remaining four horses rested and, where 
appropriate, transitioned between test diets. A minimum 2 week wash-out period was 
allowed between studies.  
7.4.3 Administration of medication 
 Two doses of omeprazole were evaluated; 1 mg/kg PO once daily and 4 mg/kg PO 
once daily.  The two doses were chosen as they are the registered GastroGard® doses for 
EGUS prevention (1 mg/kg) and treatment (4 mg/kg).  To ensure accurate dosing each 
horse was weighed on electronic scales (Accuweigh Equestrian Scales, Accuweigh, 
Willeton, WA, Australia) on day -1.  The omeprazole was administered using the 
graduated dose markings on the syringe, rounding up to the nearest 50 pound (22.7 kg) 
dose.  Omeprazole was administered at 8 am (2 hours prior to feeding in the HG/LF diet) 
for a 5 day period from day 1 – 5. 
7.4.4 Sample collection 
 An IV catheter was placed on the morning of sample collection (days 1 and 5) 
approximately 1 hour prior to the administration of the omeprazole to allow collection of the 
blood samples.  A pre-administration blood sample was collected, the omeprazole 
administered and further blood samples collected from the catheter at T= 15, 30, 45, 60, 
75, 90, 105 min and 2, 2.5, 3, 4, 6, 8 and 10 hours.  Ten mL of blood was collected on 
each occasion with 4 mL transferred to a lithium heparin tube (Vacutainer®, BD, North 
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Ryde, NSW, Australia). The samples were separated by centrifugation at 3,500 g for 10 
min immediately following collection and the plasma frozen (-20 oC) within 30 min of 
collection.  
7.4.5 Sample extraction and determination of plasma omeprazole concentration  
 Prior to analysis, plasma samples were allowed to thaw at room temperature and a 
protein precipitation extraction was performed; 100 µL of the sample was added to a 1.5 
mL Eppendorf tube and 200 μL of a methanol: acetone mix at a ratio of 80:20 was added. 
The solution was then mixed by vortexing for 15 seconds, followed by centrifugation of the 
mixture at 15,000 g for 10 min. The supernatant was collected and the plasma omeprazole 
concentration determined by ultra-high pressure liquid chromatography-mass spectrometry 
(UHPLC-MS) analysis as recently described [100].   
The magnitude of intra-run variability was determined by calculating the coefficient 
of variation of the values for the replicates of the calibration curve samples determined at 
the beginning, middle and end of each run.  Inter-run variability was determined by 
calculating the coefficient of variation between runs for each calibration point using 
average values within each run.  Accuracy of the analysis was determined by calculating 
the coefficient of determination for the calibration curve using Microsoft Excel®'s (Microsoft, 
Redmont, WA, USA) graphing function. 
7.4.6 Pharmacokinetic evaluation 
 The pharmacokinetic calculations were carried out by non-compartmental 
assessment of the data using an open source pharmacokinetic program (PK Solver, China 
Pharmaceutical University, Niinjing, China) [96]. Maximum plasma concentration (Cmax) in 
plasma and the time required to reach Cmax (Tmax) was directly calculated from the data by 
the software program.  The elimination rate constant (lambda-z) was estimated by log-
linear regression of concentrations observed during the linear phase of elimination, using 
at least three data points automatically selected by the program and confirmed by visual 
examination of the plotted data.  The area under the concentration vs. time curve (AUC0–∞) 
was calculated using the linear trapezoidal rule.  
7.4.7 Data analysis 
 Data were analysed using a computer software program (SPSS). Data were 
assessed for normality visually and using the Kolmogorov-Smirnov test with Dallal-
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Wilkinson-Lille for P values. The data were non-parametric so were log transformed to 
allow parametric analysis. A repeated measures ANOVA with Tukey’s post-test was 
performed to compare the AUC0-∞, Cmax, Tmax and half-life in each feed/dose variation (1 
mg/kg on the HAY diet, 1 mg/kg on the HG/LF diet, 4 mg/kg on the HAY diet, 4 mg/kg on 
the HG/LF diet) on days 1 and 5. Paired t-tests were used to compare day 1 of treatment 
with day 5 of treatment for each feed/dose variation. Significance was set at P≤0.05. 
Summary statistics are expressed as mean (± SD) or geometric mean with corresponding 
95% confidence intervals (95%CI). Inter- and intra-run variability’s are reported as median 
[inter-quartile range: IQR]. 
7.5 Results 
  All horses successfully completed the study and no adverse events were 
noted. The actual dose of omeprazole given ranged from 1.01-1.012 mg/kg in the 1 mg/kg 
group and from 4.00-4.12 mg/kg in the 4 mg/kg group.  A complete data set for all horses 
at all times was available.  All sample concentrations fell within the standard curve.  
Median intra-run variability for omeprazole concentration was 10.9% [IQR: 6.4 – 33.6 %].  
Median inter-run variability was 13.7% [IQR: 13.4 – 14.6 %]. The median coefficient of 
determination (R2) for the calibration curve was >0.99 for all runs.  
 Figure 7.1 shows scatter plots for AUC0-∞, Cmax, Tmax and half-life for each of the 
feed/dose variations. Table 7.1 shows mean and 95% confidence AUC0-∞, Cmax, Tmax and 
half-life for each of the feed/dose variations. 
Effect of dose 
On day one there was an increase in the AUC0-∞  on the 4 mg/kg dose compared to 
the 1 mg/kg dose on the HG/LF diet (7.63 (95%CI: 2.63-22.12) µg.min/mL vs. 1.16 
(95%CI: 0.44-3.04) µg.min/mL, p=0.039). On day five there was a trend towards the AUC0-
∞  being higher on the 4 mg/kg dose when compared to the 1 mg/kg dose on the HG/LF 
diet (14.36 (95%CI: 4.84-42.59) µg.min/mL vs. 2.01 (95%CI: 0.90-4.48) µg.min/mL, 
p=0.052). There was no difference in the AUC0-∞  on the 1 mg/kg dose compared to the 4 
mg/kg on the HAY diet on day 1 (0.87 (95%CI: 0.51-1.48) µg.min/mL vs. 4.50 (95%CI: 
0.95-21.48) µg.min/mL, p=0.14) or day 5 (0.94 (95%CI: 0.41-2.13) µg.min/mL vs. 4.37 
(95%CI: 0.89-21.59) µg.min/mL, p=0.25).  
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On day one the Cmax was higher on the 4 mg/kg dose than on the 1 mg/kg dose on 
the HG/LF diet (0.077 (95%CI: 0.021-0.283) µg/mL vs. 0.012 (95%CI: 0.004-0.033) µg/mL, 
p=0.048). One day five there was a trend towards the Cmax being higher on the 4 mg/kg 
dose than on the 1 mg/kg dose on the HG/LF diet (0.134 (95%CI: 0.035-0.506) µg/mL vs. 
0.022 (95%CI: 0.010-0.051) µg/mL, p=0.089). There was no difference in the Cmax on the 1 
mg/kg dose compared to the 4 mg/kg on the HAY diet on day 1 (0.010 (95%CI: 0.001-
0.017) vs. 0.060 (95%CI: 0.011-0.340), p=0.18) or day 5 (0.011 (95%CI: 0.000-0.030) vs. 
0.024 (95%CI: 0.003-0.182), p=0.78).  
There was no difference in the Tmax on the 1 mg/kg dose compared to the 4 mg/kg 
dose on the HG/LF diet on day 1 (37.4 (95%CI: 18.5-75.4) minutes vs. 62.1 (95%CI: 33.1-
116.4) minutes, p=0.57) or day 5 (45.9 (95%CI: 32.1-65.6) minutes vs. 43.1 (95%CI: 20.3-
91.6) minutes, p=0.99). There was no difference in the Tmax on the 1 mg/kg dose 
compared to the 4 mg/kg on the HAY diet on day 1 (28.6 (95%CI: 14.4-56.9) minutes vs. 
38.6 (95%CI: 28.3-52.5), p=0.59) or day 5 (37.4 (95%CI: 25.2-55.6) minutes vs. 43.3 
(95%CI: 13.7-136.8) p=0.99).  
There was no difference in the half-life on the 1 mg/kg dose compared to the 4 
mg/kg dose on the HG/LF diet on day 1 (50.6 (95%CI 34.9-73.5) minutes vs. 69.8 (95%CI 
40.2-121.1) minutes, p=0.57) or day 5 (50.2 (95%CI 34.2-73.7) minutes vs. 54.3 (95%CI 
37.2-79.4) minutes, p=0.99). There was no difference in the half-life on the 1 mg/kg dose 
compared to the 4 mg/kg on the HAY diet on day 1 (42.9 (95%CI 22.4-82.1) minutes vs. 
60.3 (95%CI 46.1-78.9) minutes, p=0.59) or day 5 (42.4 (95%CI 25.1-71.6) minutes vs. 
83.2 (95%CI 42.6-162.4) minutes, p=0.99).  
Effect of diet 
There was no difference in the AUC0-∞  on the HAY diet compared to the HG/LF diet 
on the 1 mg/kg dose on day one (0.87 (95%CI: 0.51-1.48) µg.min/mL vs. 1.16 (95%CI: 
0.44-3.04) µg.min/mL, p=0.14) nor on day five (0.93 (95%CI: 0.44-3.04) µg.min/mL vs. 
2.01 (95%CI: 0.90-4.48) µg.min/mL, p=0.25). There was no difference in the AUC0-∞ on the 
HAY diet compared to the HG/LF diet on the 4 mg/kg dose on day one (4.50 (95%CI: 0.94-
21.48) µg.min/mL vs. 7.63 (95%CI: 2.63-22.12) µg.min/mL, p=0.89) nor on day five (4.37 
(95%CI: 0.89-21.59) µg.min/mL vs. 14.36 (95%CI: 4.84-42.59) µg.min/mL, p=0.17) 
There was no difference in the Cmax on the HAY diet compared to the HG/LF diet on 
the 1 mg/kg dose on day one (0.010 (95%CI: 0.006-0.017) µg/mL vs. 0.012 (95%CI: 
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0.004-0.030) µg/mL, p=0.83) nor on day five (0.011 (95%CI: 0.004-0.030) µg/mL vs. 0.022 
(95%CI: 0.010-0.050) µg/mL, p=0.56). There was no difference in the Cmax on the HAY 
diet compared to the HG/LF diet on the 4 mg/kg dose on day one (0.060 (95%CI: 0.011-
0.342) µg/mL vs. 0.077 (95%CI: 0.021-0.283) µg/mL, p=0.99) nor on day five (0.024 
(95%CI: 0.003-0.182) µg/mL vs. 0.134 (95%CI: 0.035-0.506) µg/mL, p=0.28).  
There was no difference in the Tmax on the HAY diet compared to the HG/LF diet on 
the 1 mg/kg dose on day one (28.6 (95%CI: 14.4-56.9) minutes vs. 37.4 (95%CI: 25.2-
55.6) minutes, p=0.92) nor on day five (37.4 (95%CI: 26.2-55.6) minutes vs. 45.9 (95%CI: 
32.1-65.6) minutes, p=0.84). There was no difference in the Tmax on the HAY diet 
compared to the HG/LF diet on the 4 mg/kg dose on day one (38.6 (95%CI: 28.3-52.5) 
minutes vs. 62.1 (95%CI: 33.1-116.4) minutes, p=0.32) nor on day five (43.3 (95%CI: 
13.7-136.8) minutes vs. 43.1 (95%CI: 20.3-91.6) minutes, p>0.999).  
There were no differences in the half-life on the HAY diet compared to the HG/LF 
diet on the 1 mg/kg dose on day one (42.9 (95%CI: 22.4-82.1) minutes vs. 50.6 (95%CI: 
34.9-73.5) minutes, p=0.91) nor on day five (42.4 (95%CI: 25.2-71.6) minutes vs. 50.2 
(95%CI: 34.2-73.7) minutes, p=0.95). There was no difference in the half-life on the HAY 
diet compared to the HG/LF diet on the 4 mg/kg dose on day one (60.3 (95%CI: 46.1-78.9) 
minutes vs. 69.8 (95%CI: 40.2-121.1) minutes, p=0.91) nor on day five (83.2 (95%CI 42.3-
162.4) minutes vs. 54.3 (95%CI 37.2-79.4), p=0.37).  
Combined effect of dose and diet 
On day one, the AUC was higher in horses receiving the 4 mg/kg dose on the 
HG/LF diet compared to those receiving the 1 mg/kg dose on the HAY diet (7.63 (95%CI: 
2.63-22.12) µg.min/mL vs. 0.87 (95%CI: 0.51-1.48) µg.min/mL, p=0.036). This effect was 
also present on day 5 (14.36 (95%CI: 4.84-42.59) µg.min/mL vs. 0.93 (95%CI: 0.41-2.13) 
µg.min/mL, p=0.004). There were no other significant dose/diet interactions of the AUC on 
days one and five. 
On day one the Cmax was higher in horses receiving the 4 mg/kg dose on the HG/LF 
diet compared to those receiving the 1 mg/kg dose on the HAY diet (0.077 (95%CI: 0.021-
0.283) µg/mL vs. 0.010 (95%CI: 0.006-0.017) µg/mL, p=0.034). This effect was also 
present on day five (0.134 (95%CI: 0.035-0.506) µg/mL vs. 0.011 (95%CI: 0.004-0.030) 
µg/mL, p=0.02). There were no other significant diet/dose interactions of Cmax on days one 
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and five. There were no significant diet/dose interactions of Tmax and half-life on days one 
and five. 
Effect of time 
The AUC0-∞ was higher on day 5 compared to day 1 when horses were receiving 
the 4 mg/kg dose on the HG/LF diet (14.4 (95%CI: 4.8-42.6) µg
.
min/mL vs. 7.6 (95%CI: 
2.6-22.1) µg.min/mL (p=0.046)). There were no further differences between the half-life, 
Tmax, Cmax or AUC0-∞ on day 1 vs. those on day 5 for any of the feed and dose variations.  
7.6 Discussion 
To the authors’ knowledge the relative pharmacokinetics of different doses of 
omeprazole has not been previously reported in the horse. Further, the impact of diet has 
been poorly investigated.  The findings of the present study suggest that an effect of dose 
and, to a lesser extent, diet may be present on some pharmacokinetic variables of 
omeprazole in the horse.  Mean AUC0-∞ and Cmax values for 4 mg/kg were consistently 
higher than for 1 mg/kg with the effect significant on day 1 for both AUC0-∞ and Cmax. 
Likewise, mean AUC0-∞ and Cmax values for the HG/LF diet were consistently higher than 
values for the HAY diet, although the effect was not significant at any time point.  However, 
when the effect of diet and dose were considered together a significant effect was present 
on day 5 with the HG/LF diet at 4 mg/kg having a higher AUC0-∞ and Cmax than the HAY 
diet at 1 mg/kg suggesting that both diet and dose may influence both AUC0-∞ and Cmax.  In 
contrast, no effect of diet or dose was present on half-life or Tmax suggesting that these 
variables are not affected by diet or dose.  Both AUC0-∞ and Cmax were consistently 
approximately 5 – 7 times higher with the 4 mg/kg dose when compared with the 1 mg/kg 
dose.  The magnitude of this increase is greater than the 4-fold increase in dose and 
suggests that dose linear pharmacokinetics may not be present in the horse.  Further 
studies are needed to define this effect, but until further documented the authors consider 
that the extrapolation across doses as previously reported [69] to be inappropriate.   
The inability to demonstrate a consistent effect of diet may be related to a number 
of factors including the magnitude of any such effect being relatively small, or due to a 
lower than adequate power to detect such an effect in the present study.  The small 
number of animals and the wide degree of variability in the data, as evidenced by the wide 
95% confidence intervals, suggests that low power may be relevant and warrants 
consideration in the interpretation of the results. The clinical relevance of these findings is 
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unclear as the relationship between pharmacokinetics and pharmacodynamics of 
omeprazole in the horse has not been described to date.  However, in humans [102] and 
dogs [110] the primary determinant of omeprazole efficacy is AUC, and, as such, 
conditions that increase AUC may increase the efficacy of omeprazole.   
A cumulative effect of dosing was present under conditions that favored omeprazole 
absorption, namely the HG/LF diet, and the higher (4 mg/kg) dose.  The inability to 
demonstrate a consistent cumulative effect is consistent with previous reports in the horse 
[3,78] but contrasts to findings in man where AUC increases with repeated administration 
of 20 mg once daily [79].  In man it has been suggested that repeated administration of 
omeprazole may result in impaired clearance due to inhibition of the cytochrome p-450 
elimination pathway by either omeprazole or a sulphone metabolite [79].  Alternatively, it 
has also been proposed that a self-protective effect, wherein subsequent doses of 
omeprazole are protected by the increase in intra-gastric pH that occurs following 
administration of previous doses, may be present [79].   Either effect may be favoured by 
higher doses and conditions that enhance absorption with either increased accumulation 
of inhibitory metabolites, or greater efficacy in intra-gastric acid suppression, theoretically 
plausible.  Further work to elucidate the relationship between the pharmacokinetics and 
pharmacodynamics, and the inter-play between dose and diet, of omeprazole in the horse 
would be advantageous in elucidating both the relationship between pharmacokinetics and 
pharmacodynamics, and the relative impact of the proposed mechanisms for the 
cumulative effect observed at the higher dose with the HG/LF diet. 
One potential weakness of the study is that the horses in the high grain/low fibre 
diet were not specifically fasted.  However, it has recently been reported that many stabled 
horses finish an evening meal before midnight [113], an effect observed by the authors of 
the present study wherein the entire meal in the high grain/low fibre group was consistently 
consumed within 4 hours.  This effectively resulted in a fast of approximately 10 hours 
prior to the morning administration of the medication.  Further, the HG/LF diet was chosen 
as it is typical of the diet of Australian Thoroughbred racehorses [80,117] and as such the 
authors propose that it represents the clinical scenario more accurately.     
Another potential weakness is that the presence of the PEG tube and gastropexy 
may have altered gastric motility.  The use of PEG instrumented horses allowed for the 
concurrent measurement of intra-gastric pH as part of separate studies investigated the 
pharmacodynamics of omeprazole in the horse (chapter 6).  A potential effect of the PEG 
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tube and gastropexy via alterations in gastric motility and emptying on the 
pharmacokinetics reported in this study cannot be completely discounted.  However the 
author’s consider it unlikely as the reported values for Tmax, the parameter most likely to be 
affected by alterations in motility, were similar to previously reported values using the 
same formulation [3,104].    
7.7 Conclusions 
In conclusion the findings of the present study suggest that both dose and diet may 
affect some pharmacokinetic variables of omeprazole in the horse.  Further, a cumulative 
effect of repeated administration was present under certain conditions.  Further studies to 
elucidate the relationship between the pharmacokinetics and pharmacodynamics, and the 
inter-play between dose and diet, of omeprazole in the horse would be advantageous.  
Such studies may benefit from reducing the number of variables, such as diet, dose and 
formulation, investigated on each occasion.  Further, higher doses may warrant 
investigation.    
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Table 7.1 - Mean and 95% confidence intervals for Area-Under-the-Curve (AUC0-∞), Cmax, Tmax and half-life on days 1 and day 5 for the 
two doses (1 mg/kg and 4 mg/kg orally once daily) and two diets (high grain/low fiber (HG/LF) and ad libitum hay (HAY)). Groups with the 
same superscript letter are statistically different from each other (p<0.05). 
1 mg/kg 
 HG/LF HAY 
Day 1 Day 5 Day 1 Day 5 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
AUC0-∞ 
(µg.min/ml) 
1.16a 0.44-3.04 2.01 0.90-4.48 0.87c 0.51-1.48 0.94d 0.41-2.13 
Cmax (µg/ml) 0.012
b 0.004-0.033 0.022 0.010-0.051 0.010e 0.001-0.017 0.011f 0.000-0.030 
Tmax (min) 37.4 18.5-75.4 45.9 32.1-65.6 28.6 14.4-56.9 37.4 25.2-55.6 
Half-life (min) 50.6 34.9-73.5 50.2 34.2-73.7 42.9 22.4-82.1 42.4 25.1-71.6 
4 mg/kg 
 HG/LF HAY 
Day 1 Day 5 Day 1 Day 5 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
AUC0-∞ 
(µg.min/ml) 
7.63a,c,g 2.63-22.12 14.36d,g 4.84-42.59 4.50 0.95-21.48 4.37 0.89-21.59 
Cmax (µg/ml) 0.077
b,e 0.021-0.283 0.134f 0.035-0.506 0.060 0.011-0.342 0.024 0.003-0.182 
Tmax (min) 62.1 33.1-116.4 43.1 20.3-91.6 38.6 28.3-52.5 43.3 13.7-136.8 
Half-life (min) 69.8 40.2-121.1 54.3 37.2-79.4 60.3 46.1-78.9 83.2 42.6-162.4 
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Figure 7.1 –  Scatter plots of Area-Under-the-Curve (AUC0-∞), Cmax, Tmax and half-life on days 1 and day 5 for the two doses (1 mg/kg and 
4 mg/kg orally once daily) and two diets (high grain/low fiber (HG/LF) and ad libitum hay (HAY)). Groups with the same superscript letter 
are statistically different from each other (p<0.05). 
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Chapter 8 – Pharmacokinetic/pharmacodynamic modelling of omeprazole in the 
horse 
8.1 Introduction 
In dogs [110,118] and humans [102] the gastric anti-secretory effect of omeprazole 
is related to the area under the plasma concentration curve.  The objective of this study 
was to preliminarily investigate whether such an effect was present in the horse utilising 
pharmacokinetic and pharmacodynamic data collected concurrently in study 5. 
8.2 Materials and Methods 
8.2.1 Animals, group allocations, sample collection and analysis  
Horses were allocated and managed as outlined in chapter 6.  Concurrent 
pharmacodynamic and pharmacokinetic measurements were performed on days 1, 3 and 
5.  Pharmacodynamic measurements were performed as outlined in chapter 6.  Collection 
and analysis of plasma samples was performed as outlined in chapter 7.  Pharmacokinetic 
analysis was performed as outlined in chapter 7.   
8.2.2 Data analysis 
 Data for mean intra-day pH, median intra-day pH and the percentage time pH was 
above 4 (%tpH>4) for both measurement points (measurement point 1 and measurement 
point 2) and the three days (days 1, 3 and 5) were screened graphically for correlations 
against the key pharmacokinetic variables (Cmax and AUC0-∞).  Spearman's correlation 
coefficients were used, with coefficients  <0.4 regarded as poor, 0.4–0.7 moderate and 
>0.7 good [108].   
8.3 Results 
 All horses successfully completed the study and no adverse events were noted. 
Median intra-run variability for omeprazole concentration was 10.9% [IQR: 6.4 – 33.6 %].  
Median inter-run variability was 13.7% [IQR: 13.4 – 14.6 %]. The median coefficient of 
determination (R2) for the calibration curve was >0.99 for all runs. 
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 Due to technical errors with intra-gastric pH measurement, data was not available 
for 2 horses on day 1 (both HG/LF diet and 1 mg/kg dose), one horse on day 3 (HG/LF 
diet and 4 mg/kg dose) and one horse one day 5 (HAY diet and 4 mg/kg dose).  Plasma 
omeprazole concentrations peaked at 0.001 μg/mL (the limit of quantification) in one horse 
on days 3 and 5 (HG/LF diet and 1 mg/kg dose) and did not allow calculation of AUC0-∞.  
Where either the intra-gastric pH measurements or the key pharmacokinetic variables 
were not available the entire data for that time point was excluded.  This resulted in a total 
of 66 complete data sets available for comparison.   
 Figures 8.1 – 8.6 show key pharmacodynamic variables (mean intra-day pH, 
median intra-day pH and %tpH>4) plotted against Cmax.  Figures 8.7 – 8.12 show key 
pharmacodynamic variables (mean intra-day pH, median intra-day pH and %tpH>4) 
plotted against AUC0-∞.  All correlation coefficients were classified as poor (<0.4). 
8.4 Discussion 
 In the present study no correlation between either of the pharmacokinetic 
parameters (AUC and Cmax) and pharmacodynamic parameters (mean intra-day pH, 
median intra-day pH and (%tpH>4) could be demonstrated.  This is in contrast to studies 
in dogs [110,118] and humans [102] where the gastric anti-secretory effect is related to the 
area under the plasma concentration curve. 
 The reasons for the failure to observe such an effect is unclear.  The number of 
animals in the present study was small although studies in dogs have used as little as 
three dogs to accurately model pharmacokinetic/pharmacodynamic data [110]. 
Alternatively the overall poor low Cmax and AUC values observed in the present project 
may explain the lack of correlations.  Examination of the scatter plots in figures 8.1 – 8.12 
reveals a clustering of data points at the low end of both scales with a wide range of 
corresponding mean intra-day pH, median intra-day pH and %tpH>4 values.  Lastly, the 
impact of meal feeding on baseline pH measurements in the HG/LF diet may have 
distorted the data.  Equally plausible is the impact of continuous feeding in the hay diet.  
Human and dog studies are typically conducted in fasted patients and the effect of a large 
bolus of food in the stomach, especially a stomach as large as the horses, is not known. 
Further modelling of subsets of the data focusing on higher doses and conditions that 
results in better absorption (HG/LF diet or fasted animals) may result in more reliable 
modelling and warrants consideration. 
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Figure 8.1 - Mean intra-day pH vs. Cmax at measurement point 1. All data points from days 1 and 5 from a four-way cross over 
study design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high 
grain/low fibre diet) are included. 
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Figure 8.2 - Mean intra-day pH vs. Cmax at measurement point 2. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
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Figure 8.3 - Median intra-day pH vs. Cmax at measurement point 1. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
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Figure 8.4 - Median intra-day pH vs. Cmax at measurement point 2. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
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Figure 8.5 - %tpH>4 vs. Cmax at measurement point 1. All data points from days 1 and 5 from a four-way cross over study design 
evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low fibre 
diet) are included. 
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Figure 8.6 - %tpH>4 vs. Cmax at measurement point 2. All data points from days 1 and 5 from a four-way cross over study design 
evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low fibre 
diet) are included. 
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Figure 8.7 - Mean intra-day pH vs. AUC0-∞ at measurement point 1. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
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Figure 8.8 - Mean intra-day pH vs. AUC0-∞ at measurement point 2. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
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Figure 8.9 - Median intra-day pH vs. AUC0-∞ at measurement point 1. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
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Figure 8.10 - Median intra-day pH vs. AUC0-∞ at measurement point 2. All data points from days 1 and 5 from a four-way cross over study 
design evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low 
fibre diet) are included. 
  
y = 0.0786x + 2.3351 
R² = 0.3959 
0
1
2
3
4
5
6
7
8
9
0 5 10 15 20 25 30 35 40 45 50
M
ed
ia
n
 In
tr
a
-D
ay
 p
H
 
AUC0-∞ (µg
.min/mL) 
141 
 
Figure 8.11 - %tpH>4 vs. AUC0-∞ at measurement point 1. All data points from days 1 and 5 from a four-way cross over study design 
evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low fibre 
diet) are included. 
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Figure 8.12 - %tpH>4 vs. AUC0-∞ at measurement point 2. All data points from days 1 and 5 from a four-way cross over study design 
evaluating the effects of 2 doses (1 mg/kg and 4 mg/kg/day PO once daily) and 2 diets (an ad libitum hay diet and a high grain/low fibre 
diet) are included. 
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Chapter 9 – General Discussion 
Equine Gastric Ulcer Syndrome (EGUS) is arguably the most prevalent disease of 
the athletic horse with a prevalence of up to 100% reported in competing horses in some 
studies [19].  Up to 93% of Thoroughbred horses in training [19] and competing endurance 
horses [28] have ESGD and a prevalence of ESGD exceeding 50% has been reported in a 
wide range of other horse use types [29–32].  Similarly, a prevalence of EGGD exceeding 
50% has been reported in a wide range of horse use types studies [8,31,33,34,38]. 
Omeprazole is considered the treatment of choice [1], supported by clinical studies that 
document its efficacy over other treatment options [50,68].  However, the typical response 
rate reported in clinical studies assessing omeprazole at 4 mg/kg PO once daily for 28 
days, the most commonly used dose globally, is only approximately 70 – 80% for ESGD 
[5–7,49,50].  Further, in studies performed by the authors in the lead up to this thesis it 
was demonstrated that the healing rate decreases to 25% for EGGD lesions under similar 
conditions [8–10].  To date the failure of approximately 20 – 30% of horses with ESGD and 
approximately 75% of horses with EGGD to heal has been poorly investigated.   
 Considering this the aim of the present project was to investigate the factors that 
affect the pharmacokinetics and pharmacodynamics of omeprazole in the horse with the 
ultimate aim of elucidating potential explanations for the variability in treatment response 
described above.  To achieve this, the project was conducted in three parts; 
- Part 1: This formed a preliminary evaluation of the factors that affect the 
pharmacokinetics of omeprazole in the horse.  The effects of feeding and 
formulation were evaluated in three studies; 
- Part 2: This involved the development and validation of a modified technique of 
intra-gastric pH measurement in the horse; 
- Part 3: This involved integration of the findings from part 1 with the model 
developed in part 2 for a detailed assessment of the pharmacokinetics and 
pharmacodynamics of omeprazole over a 5 day period.  Further, an attempt was 
made to correlate the pharmacokinetic data with the pharmacodynamic data. 
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Part 1 
Study 1  
The initial study in the project, as reported in chapter 2, evaluated the 
pharmacokinetics of an enteric coated formulation and a plain formulation of omeprazole.  
At the time of study execution little was published on the pharmacokinetics of enteric 
coated omeprazole with the data that was available incomplete due to the inability to 
detect plasma concentrations in several animals in each study [4,78].  Further, the effect of 
feeding on the pharmacokinetics of enteric coated omeprazole had not previously been 
reported, in contrast to buffered omeprazole where the impact appears to be marked [3], 
nor had the pharmacokinetics of plain, unprotected omeprazole been determined.   
 The findings of the study were an overall bioavailability of a single dose for the 
enteric coated omeprazole in the fasted horse of 22% [100].  This is greater than 
previously reported under similar conditions with previous reports ranging from 6% [4] to 
12% [78].  The most likely explanation for the greater bioavailability observed is that the 
analytical technique used (UHPLC) in the present study is more sensitive than the 
technique used in the earlier reports (HPLC).  This is evidenced in part by the current 
technique’s ability to detect plasma concentrations in all animals and under all conditions 
studied in the current project (although AUC could not be calculated at 2 time points due to 
the very low concentrations reported as detailed in chapter 7).  It is particularly relevant in 
the measurement of AUC as the cumulative effect of the tail on the right hand side of the 
AUC plot can dramatically impact on the overall AUC recorded.  Alternative explanations 
for the greater bioavailability observed include the specific formulation evaluated and dose 
used (4 mg/kg PO vs. 0.7 mg/kg PO [78] and 1.4 mg/kg PO [4]).  These two factors were 
further evaluated in studies number 3 (reported in chapter 4) and number 5 (reported in 
chapter 7), respectively. 
 The findings of the study supported the recommendation that omeprazole be 
protected against gastric acidity [11] as the bioavailability of the plain, unprotected 
omeprazole (10%) was approximately half of the enteric coated formulation (22%). It 
should be noted that chapter 2 it is reported that a generic formulation of plain, 
unprotected omeprazole had recently been released onto the European market 
(Peptizole®).  At the time of writing and based on the information available at the time this 
information was considered accurate as this was the manner in which the formulation was 
marketed.  Recently the manufacturers of the aforementioned product have clarified that 
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their product is indeed buffered, primarily as a response to the ECEIM consensus 
statement [1] that clearly outlines the need to distinguish between different formulation 
types of omeprazole.  Considering the low bioavailability found in study 1 and the absence 
of commercially available plain formulations, further evaluation of plain, unprotected 
formulations was not deemed justified.   
 The third, potentially significant finding of study 1 was the observation of wide range 
in bioavailability between individual animals. Three of 12 horses appeared to absorb 
omeprazole poorly, regardless of the formulation or feeding status studied.  These findings 
are largely understated in the early studies outlining the pharmacokinetics of omeprazole 
in the horse, although a 1999 publication by Daurio [3] hinted at such an effect.  In that 
study, plasma AUC’s with a standard deviation up to 80% of the mean value were reported 
although the presentation of the data as mean ± S.E. meant that the magnitude of the 
variation was less obvious on initial review.  The finding that 25% of horses appeared to 
absorb omeprazole poorly was interesting as it appears to correlate well with the reported 
20 – 30% treatment failure rate for ESGD under clinical conditions, leading the authors to 
speculate that individual variation in the absorption of omeprazole may be a key 
contributory factor in the observed therapeutic failure rates. 
The final finding of study 1 was that the bioavailability of enteric coated omeprazole 
did not appear to be significantly affected by feeding.  This is in direct contrast to a 
previous reported for a buffered formulation of omeprazole wherein feeding reduced the 
bioavailability, as measured by AUC, to approximately 1/3 of fed values [3]. This finding 
provided the justification for study 2 of the current project. 
Study 2 
 As discussed above the primary justification for study 2 was the finding that the 
impact of feeding on an enteric coated formulation was less than previously reported for a 
buffered formulation of omeprazole suggesting that there may be an interaction between 
formulations and feeding.  Such an interaction would be potentially relevant in formulations 
dosing recommendations. 
 The findings of the study were consistent with previous studies with feeding 
resulting in a reduction of median AUC to 57% and 49% of fasted values in the enteric 
coated and buffered formulation, respectively.  Although a statistically significant effect of 
feeding was not found in the present study, likely due to the wide variation in the data, 
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these findings, in conjunction with previous reports [3,100], formed the justification for 
inclusion of diet as a key variable of interest in part 3 of the project.   
Study 3 
The third study evaluated the relative pharmacokinetics of 5 different formulations of 
omeprazole.  At the time of study execution there was no published data on the relative 
bioavailability of different formulations of omeprazole beyond that reported in chapter 2.  
Interest in the bioavailability of different formulations is particularly pertinent to the 
Australian market as both enteric coated and buffered formulations of omeprazole are 
available commercially.  The manufacturers of enteric coated omeprazole claim higher 
bioavailability (c.f. buffered formulations) yet, to the authors’ knowledge, no published data 
exists to support this claim.  Between study execution and publication an independent 
report refuted this claim reporting no difference between the relative bioavailability of 
Gastrozol® at 1 mg/kg PO once daily and GastroGard® at 4 mg/kg PO once daily [69].  
Further, no difference in endoscopic healing was observed between the two formulations 
[69] consistent with a study performed by the current authors wherein doses of an enteric 
coated formulation as low as 1 mg/kg PO once daily were shown to be as efficacious as 4 
mg/kg PO once daily [8]. If the different formulations of omeprazole were equivalent then 
the implications are significant as the potential to use lower doses would result in 
significant cost savings to horse owners, potentially increasing the number of animals 
treated.  As outlined in chapter 4, GastroGard® was chosen as the reference formulation 
as it is the best recognised internationally. 
The findings of the study were that no differences were present between the enteric 
coated formulations, and one of the buffered formulations and GastroGard® (Merial, USA).  
These findings were consistent with the independent report [69] aforementioned.  A longer 
Tmax and lower Cmax were present between the fourth test formulation (Abgard
®) and 
GastroGard
®
 but the significance of these clinically is questionable based on previous 
published reports of the formulation’s efficacy in clinical patients [9,119].  Bioequivalence 
could not be demonstrated for any of the formulas against GastroGard®.  This is likely in 
part due to the small number of animals included in the study but examination of the raw 
data suggests that small, differences may be present although the clinical significance of 
these is unknown.   
The lack of demonstrable bioequivalence was the primary justification for inclusion 
of GastroGard® as the formulation investigated in the part 3 of the project in that although 
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the other formulations were not demonstrated to be different they equally were not 
demonstrated to be the same.  As such, GastroGard® was chosen as it is formulation best 
recognised internationally and it is generally considered the reference formulation.   
The lack of a significant difference between the formulations was also the 
justification for inclusion of the low (1mg/kg PO once daily) dose in the final study.  As 
discussed above two studies have found no difference in endoscopic outcome between 1 
mg/kg PO once daily and 4 mg/kg PO once daily [8,69] raising the question whether lower 
doses may be equally efficacious for treatment.  
Part 2 
 As discussed in chapter 6; several key limitations are present in the models that 
have been previously used to investigate intra-gastric pH in the horse.  Of the previously 
used models the indwelling pH probe model fitted retrograde through a gastric cannula is 
arguably the most relevant to clinical conditions as it allows recording of intra-gastric pH 
under clinically relevant dietary conditions.  The main downside of the previously described 
model [11] is the need for general anaesthesia and advanced surgical skill.  The technique 
described in chapter 5 results in a comparable model for intra-gastric pH measurement 
while removing these disadvantages.  The procedure was well tolerated and repeatable 
measurements of intra-gastric pH were recorded over the 5 day study period.  At the time 
of writing the 6 instrumented horses used in study 5 have been maintained with indwelling 
PEG tubes for periods of 18 – 24 months and continue to be used in on-going studies.  
The primary disadvantage of the current model is that the fixed location of the probe only 
allows measurement at a specific anatomical location in the stomach.  Given that pH within 
the horses’ stomach is stratified [40], it is important to note that measurement of intra-
gastric pH in the present model is reflective in ventral gastric pH and may not be reflective 
of acidity in other regions of the stomach.  Further, although well tolerated, placement of 
the PEG tubes is invasive and a period of convalescence is needed before animals can be 
used experimentally.  Lastly, it is possible that gastropexy formed by the technique may 
alter gastric motility, although based on the concurrent pharmacokinetic measurements 
performed in the current studies this does not appear likely.     
 An interesting effect of meal feeding that has not previously been described was 
observed in this study and has reliably been observed in day 0 baseline recordings 
throughout the subsequent studies.  The effect observed was a rapid rise in intra-gastric 
pH following meal feeding in the HG/LG diet as shown in figure 5.7.  A similar effect has 
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been reported in humans where, due to the buffering effects of food, intra-gastric pH is 
highest after a meal [111].  It is also likely that the ingestion of saliva plays a significant 
role in the increase in pH observed. In the present studies the effect was most consistently 
observed following the morning meal with a less consistent effect present in the evening 
meal.  The authors proposes that the reason behind the difference in effect at the two 
meals likely relates to the different inter-meal durations with the morning meal occurring 16 
hours after the evening meal and the evening meal 8 hours subsequent to the morning 
meal.  As such it is reasonable to expect that the stomach was emptier, and or the horse 
was hungrier and as a result ate faster, at the time of morning meal feeding which would 
exacerbated the buffering effect of a bolus of food.  As shown in table 5.1 the %tpH>4 was 
approximately 0% in the hay only diet and approximately 10% in the HG/LF diet, although 
the clinical significance of this relatively modest effect is unclear. 
Part 3 
 As discussed in part 1; based on the findings of studies 1 – 3, the key variables that 
were considered for inclusion in the final study were dose and diet.  Since formulation was 
considered less important, GastroGard® was chosen as the test formulation as it is the 
international reference standard.   
 As discussed in chapter 6; the findings of the study suggest that the use of uniform 
dosing recommendations that encompass all horse types may not be appropriate.  
Although toxicity, dose related or otherwise, associated with the administration of 
omeprazole has not been reported in the horse, in most countries the per day cost of 
omeprazole therapy at 4 mg/kg PO once daily remains high, despite the expiration of the 
GastroGard® patent in early 2014.  As such, the ability to use low dose therapy would be 
financially advantageous and would potentially allow the treatment of a greater number of 
animals due to greater affordability of the medication.   
In considering the data presented in chapter 6 the relative validity of the findings to 
ESGD and EGGD healing conditions warrants discussion.   The location of the pH probe 
within the ventral stomach provides a reliable indicator of pH in the region and the day 0 
baseline recordings consistently reported a median intra-day pH of approximately 2 which 
is comparable to previous reports [40].  The authors consider that extrapolation of the 
ventral gastric pH data to ESGD healing conditions may be appropriate in the high 
grain/low fibre diet model, as intermittent fasting has been shown to disrupt the normal 
stratification of intra-gastric pH [120].  Equally the authors consider that interpretation of 
149 
 
ESGD healing conditions using ventral gastric pH measurements is likely not appropriate 
under ad libitum hay/roughage conditions as stratification of pH from 3 in the ventral 
stomach to 7 at the level of cardia is normally present under such conditions [40].  As such 
the pH recorded at the ventral measurement points is unlikely to be indicative of pH at the 
level of the squamous mucosa under such conditions. 
Implications of the Present Study 
Formulation 
 The findings of the present project reinforce previous recommendations that 
omeprazole requires some form of protection from intra-gastric acidity to prevent its 
degradation during transit through the stomach [11]. However, they suggest that the 
method of protection used, either enteric coating or buffering, is less important than the 
presence of a protective mechanism per se at least in the fasted horse.  Whether the 
mechanism of protection has an impact of absorption in horses receiving ad libitum 
hay/roughage based diets is less clear.  The results of study 1 and 2 suggest that an 
interaction between formulation and feeding may be present wherein the impact of feeding 
on reducing bioavailability may be less pronounced in enteric coated formulations than 
buffered formulations.  No statistically significant effect could be demonstrated in the 
present project therefore the authors consider that caution should be observed in 
extrapolating the findings of the present study relating to fed conditions between 
formulation types.  Further work into the specific impact of feeding on the 
pharmacokinetics and pharmacodynamics of enteric coated omeprazole are required 
before conclusion as to its efficacy under fed conditions can be drawn. 
Dose 
Based on previous reports on the apparent efficacy of low dose (1 mg/kg PO once 
daily of an enteric coated formulation (Gastrozol®) omeprazole therapy in the treatment of 
ESGD [8,69] and the findings of the present project it appears that a recommendation of 1 
mg/kg PO once daily for the treatment of horses receiving high grain/low fibre diets is 
justified.  Based on the findings of study 3, it does not appear that the choice of a buffered 
or enteric coated formulation is likely to impact upon this recommendation as it is likely that 
horses are effectively fasted prior to administration of omeprazole each day under such 
conditions.  The efficacy of GastroGard® at 2 mg/kg PO once daily in the prevention of 
ESGD in Thoroughbred racehorses [68] and the registration of buffered omeprazole at 1 
150 
 
mg/kg (UlcerGard®, Merial, Duluth, GA, USA) appears to support this recommendation.  It 
has been demonstrated that the risk of ESGD in racehorses with once daily administration 
of an oral buffered omeprazole formulation (GastroGard®) at 2 mg/kg PO once daily does 
not differ from the risk with administration at 4 mg/kg PO once daily. 
Further, to the authors’ knowledge it has not been demonstrated that treatment 
requires a greater duration of acid suppression than prevention.  Given that the 
mechanism of treatment and prevention are identical (i.e. indirect via suppression of acid 
production) it is reasonable to consider that the efficacy of buffered formulations at 1 
mg/kg PO once daily as a prophylactic may also translate to efficacy in treatment at the 
same dose. Further, differences for time to healing and ESGD scores were not different 
between horses administered a range of dosing regimens (1.5 mg/kg PO twice daily, 3 
mg/kg PO once daily, 3 mg/kg PO twice daily and 6 mg/kg PO once daily) [95].  However, 
it should be noted that a dose response was present in study 5 and as such it is 
emphasised that several assumptions and extrapolations are made in the above 
statement. Clinical studies evaluating 1 mg/kg PO once daily of buffered omeprazole for 
the treatment of ESGD are required before a firm recommendation can be made. 
In contrast, based on the findings of the present study the use of reduced doses for 
horses receiving ad libitum hay or roughage based diets does not appear justified.  
Although both 1 mg/kg and 4 mg/kg PO once daily were equally effective in raising 
%tpH>4 and median pH, as shown in figures 6.2 and 6.3 respectively, it appears that the 
neither dose resulted in adequate suppression of acid production to allow healing of 
lesions in the ventral or glandular region of the stomach under such conditions.  Predicted 
day 5 %tpH>4 was < 40% which, based on reports in other species is inadequate for 
healing to occur.  In humans good healing rates for GERD are achieved when the %tpH>4 
exceeds 66% [88].  It warrants note that %tpH>3 is used as a benchmark for glandular 
ulcer healing in other species and may more accurately predict the efficacy of current 
dosing regimens for glandular healing than %tpH>4 with a %t>pH >3 of greater than 66% 
required in humans [88].  Unfortunately due to limitations in the software of the reporting 
program determination of %tpH>3 was not possible.  However, the duration and 
magnitude of acid suppression required for healing of either ESGD or EGGD has not been 
documented, and the authors proposes that %tpH>4 represents a more conservative 
benchmark for the investigation of acid suppressive therapy until such factors are 
documented.  This statement has been supported in a recent [85] review .   
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It is tempting to speculate that the relatively poor ability of omeprazole to raise 
ventral gastric pH under certain conditions is a potential explanation for the reported low 
healing rate of EGGD with omeprazole monotherapy [8–10].  However, more detailed 
interpretation of the published data suggests that such a conclusion may not be 
appropriate.  The conditions studied in 2 of the papers cited [8,9] included administration 1 
– 4 hours prior to feeding in a clinical scenario comparable to the model evaluated in study 
number 5.  Under such conditions the administration of 4 mg/kg PO once daily would be 
expected to result in marked suppression of acid production as shown in the high grain/low 
fibre diet in figure 6.2 where the %tpH>4 exceeded 80% from days 1-5.  This finding draws 
into question the recommendation that acid suppressive therapy form a cornerstone of the 
treatment of EGGD.  Further studies are needed to document the healing rate of EGGD 
under conditions where marked acid suppression is expected.  Further studies evaluating 
4 mg/kg PO once daily in horses receiving high grain/low roughage diets are needed 
before acid suppressive therapy can be discounted as a pre-requisite for EGGD treatment.  
Pharmacodynamic studies evaluating twice daily administration or higher doses are 
needed to determine the treatment regimen that could reasonably be expected to result in 
conditions conducive to EGGD healing.   
Feeding Recommendations 
Current feeding recommendations for the management of EGUS do not 
discriminate between ESGD and EGGD or between management during treatment and 
management during prevention.  The most common recommendations include the 
provision of ad libitum roughage, a reduction in the grain content of the diet and 
supplementation with vegetable oil [1].  These recommendations are based primarily on 
risk factors identified for ESGD and are arguably less relevant to the management of 
EGGD as dietary factors are yet to be consistently identified as risk factors for EGGD [1]. 
In particular reduction of grain content is expected to be beneficial as increased 
starch/grain intake has been associated with an increased risk of ESGD in animals 
working at various levels of intensity in a number of studies. A marked increase in 
ulceration has been observed when non–exercising animals were stabled and fed grain at 
1% of BW, 1 hour before hay was fed [47]. Similarly, exceeding 2 g/kg BW of starch intake 
per day has been associated with an approximately two-fold increase in the likelihood of 
ESGD grade ≥ 2/5 [48]. In another study, all horses developed ESGD within 14 days of 
their removal from pasture, stabling (fed 6 kg concentrate feed/day) and entering a 
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simulated training regimen [64], although it warrants note that the effects in this latter study 
are likely multifactorial. The provision of vegetable oil is logical as both total gastric acid 
output and prostaglandin concentration has been shown to decrease in ponies with gastric 
cannulas fed 45 mL corn oil orally once daily by dose syringe [121]. 
However, the benefits of ad libitum roughage are less clear and conflicting evidence 
is present in the literature as to whether pasture turn out or ad libitum roughage reduces 
the risk of ESGD.  No effect of quality of pasture, or time at pasture (stabled, stable and 
pasture, pastured) was shown on ESGD prevalence in a study of Thoroughbred 
racehorses in New Zealand [25]. Further, in a study evaluating the influence of a high fibre 
diet vs. an iso-energetic low fibre diet both the number and severity of ESGD lesions was 
greater in the high fibre diet group [122]. Together, these findings suggest that that the 
impact of forage feeding in the absence of other risk factor reduction may not be as great 
as previously believed [1].  
Considering this and the impact of ad libitum hay on the efficacy of omeprazole 
demonstrated in the present study the dietary recommendation of ad libitum roughage 
warrants discussion.   In the absence of pharmaceutical intervention the provision of ad 
libitum roughage is a small management change, one that may be advantageous and one 
that is logical to implement.  However, during treatment with omeprazole the significantly 
greater magnitude and duration of acid suppression observed with fasting should be 
considered and balanced against the potential, but unproven, benefits of ad libitum 
roughage.  Paradoxical to the common believe that ad libitum roughage is ideal, the 
authors believes that it may be advantageous to enforce a brief overnight fast prior to the 
administration of omeprazole in animals undergoing treatment.  Based on the findings of 
the current studies the duration of that fast should not be less than 10 hours as it is not 
known whether shorter duration fasts result in a similar increase in omeprazole efficacy.  
Further investigation into the effect of shorter fasting periods warrants investigation and 
determination of the shortest possible fasting period that allows a trade-off between 
omeprazole efficacy and the provision of the maximal intra-day access to roughage would 
be advantageous. The application of such an approach may be particularly useful in the 
management of EGGD as the benefits of ad libitum roughage in reducing the risk of 
disease are less clear.  As such the risk: benefit ratio of fasting shifts further in favour of 
fasting to enhance omeprazole efficacy.  The development of dosing regimens or the use 
of alternative therapeutics that result in an adequate magnitude and duration of acid 
suppression under ad libitum roughage conditions would be ideal as it would represent a 
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“best of both worlds’ situation in which nutritional management and pharmaceutical 
efficacy are both optimised.  
In addition to the enforcement of an overnight fast it is logical that feeding should 
coincide with peak plasma concentrations of omeprazole, or shortly thereafter to allow 
transportation of omeprazole in the parietal cell, as omeprazole works best when parietal 
cell activation coincides with high drug concentrations [87]. Based on the findings of the 
present studies; Tmax is ≤ 100 minutes in the majority of animals suggesting that a delay of 
approximately 1½ – 2 hours between administration of the omeprazole and feeding is 
appropriate in the horse. 
Inter-individual variability  
 As discussed in chapter 2, a wide range of inter-individual variability was observed 
in study 1 and this effect was present throughout the project.  The plotted data in figures 
8.2 – 8.5 further supports this statement with individual pharmacodynamic response highly 
variable regardless of the dose or diet studied.  The observation that approximately 25% of 
animals fail to absorb omeprazole appears to roughly correlate with the pharmacodynamic 
data from study 5 and it is tempting to speculate that this finding potentially explains the 
failure of 20 – 30% of patients with ESGD to heal in clinical studies [5–7,49,50].  Further 
investigation into the pharmacodynamics of clinical non-responders appears justified and 
the potential use of alternative therapeutics, such as ranitidine [5,39,71,72], in such 
patients warrants consideration. The failure to address predisposing factors such as diet 
[46] and high intensity exercise [45] may be confounding factors.   
Future directions 
Formulation 
 The findings of the present project suggest that little difference exists between the 
commercially available formulations, at least in the fasted state.  As discussed above 
further evaluation of the pharmacodynamics of enteric coated formulations appears 
warranted to definitively document their efficacy, although based on the findings of the 
present project the expected differences would likely be small. 
 Alternatively the investigation of different PPI’s appears justified, especially in the 
fed state.  In humans a wide range of PPI’s are used with esomeprazole one of the better 
studied.  The use of esomeprazole as the PPI of choice in humans has been supported by 
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two meta-analysis studies demonstrating its superiority over other PPI’s in treating clinical 
disease [123,124].  The use of esomeprazole has recently been described in the horse 
[90,125] and it appears to have promise as an alternative means of acid suppression that 
warrants further investigation.       
Dose 
 As discussed above investigation of higher doses or alternative regimens appears 
warranted.  Pilot investigations by the authors have suggested that 8 mg/kg PO once daily 
of GastroGard® results in rapid and profound (%tpH>4 exceeds 80% by day 1) acid 
suppression even in horses fed ad libitum hay.  As discussed above, it is unclear whether 
increased acid suppression will result in an increase in the EGGD healing rate but further 
assessment of the pharmacodynamics, and ultimately clinical efficacy, of high dose 
therapy is logical. 
 Alternatively twice daily administration warrants discussion.  No advantage of twice 
daily administration, over once daily administration, was observed in a study evaluating 
ESGD response rates over a range of doses (1.5 mg/kg PO twice daily, 3 mg/kg PO once 
daily, 3 mg/kg PO twice daily and 6 mg/kg PO once daily) [95]. In humans the predicted 
magnitude of acid suppression with omeprazole increases from 66% of maximal acid 
output with once daily administration to 80% with twice daily administration [66].  
Considering that the impact of twice daily administration appears to be modest the authors 
consider that the investigation of higher doses warrants consideration first.  Additionally 
the maintenance of a once daily administration is likely to improve compliance should 
higher dose regimens be demonstrated to be superior. 
Genetics  
 The consistent effect of inter-individual variability is an interesting finding of the 
present project.  The cause(s) of such an effect are not known.  In humans, variation in the 
efficacy of omeprazole has been reported and is primarily related to mutations in the 
CYP2C19 gene and changes in the rate of elimination of omeprazole [98].  Whether the 
poor bioavailability observed in some horses in the present project reflects increased 
clearance of omeprazole, as observed in humans, is unclear but evaluation of the genetic 
profile of the horse, with specific relevance to the CYP2C19 gene, appears warranted.  
Alternatively factors that affect the rate of absorption may be important. 
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Pharmacokinetic/pharmacodynamic modelling 
 As discussed in chapter 8 no correlation between key pharmacokinetic parameters 
and key pharmacodynamic parameters was demonstrable although the reasons for this 
are unclear.  If future studies into higher dose omeprazole support the pilot findings 
reported above and higher levels of suppression are observed with such doses then 
further investigations into pharmacokinetic/pharmacodynamic modelling may be 
warranted.   
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